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Abstract 
Stroke is a debilitating disorder with no effective treatments. The clinical importance of 
promoting cerebral ischemic tolerance is apparent; however, our knowledge of the signaling 
mechanisms involved in the phenomenon of ischemic preconditioning remains insufficient to be 
able to translate to the clinical environment.  This dissertation is aimed at an investigation of 
endogenous pathways, which are both innate and adaptive (in response to a preconditioning 
stimulus), and by which the brain might protect itself from ischemia. Defining key proteins and 
mechanisms involved in those pathways can potentially be used as tolerance-producing drugs.  
Hypoxia Inducible Factor-1α (HIF-1α) is the major regulator of oxygen homeostasis and 
functions to induce a wide array of transcripts. HIF-1’s downstream targets mediate a number of 
cellular mechanisms that can facilitate cellular adaptation to hypoxia and promote survival. We 
have sought to understand the mechanisms of HIF-1 stability and degradation and to determine 
its use as a potential therapy for the treatment of stroke (Chapter 1). In the brain, HIF-1 is present 
in neurons as well as astrocytes. Considering their important role in maintaining glutamate 
homeostasis and providing support necessary for the survival of neurons, we examined the 
effects of glutamate toxicity on the viability of astrocytes exposed to hypoxia and the role that 
HIF-1 plays under these conditions (Chapter 2). Moreover, given that glutamate toxicity is 
responsible for the majority of the damage that occurs after ischemia, we aimed to better 
understand the mechanisms of tolerance induced by adaptation to chronic levels of glutamate 
(Chapter3).  
Overall, in this thesis we identified novel pathways that promote neuronal and astrocytic 
survival after ischemia. First, we demonstrated that HIF-1α oxidation by the formation of 
reactive oxygen species during ischemia increased its susceptibility to degradation by the 20S 
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proteasome. Proteasome inhibition increased HIF-1 accumulation and reduced ischemia- induced 
neurotoxicity. Next, we observed that stabilization of HIF-1α under hypoxia has a protective 
effect on astrocytes in maintaining cell morphology and viability in response to glutamate 
toxicity. We found that the presence of the antioxidant, glutathione, was correlated with an 
increased expression of HIF-1α and its inhibition decreased HIF-1α protein levels and cell 
viability. Finally, for the first time we show that an in vivo model of glutamate preconditioning 
was also able to induce tolerance and decrease brain infarct volume in addition to edema volume 
in both young adult (9-month) and aged (22-month) mice. Taking advantage of these 
mechanisms may lead to the development of more feasible and less dangerous therapeutic agents 
and approaches to treat ischemic strokes.  
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Chapter 1: Introduction 
1.1 Background and Significance 
Stroke 
Stroke is the third leading cause of death in the United States, resulting in approximately 
133,000 deaths every year (Lopez et al., 2006). Worldwide, stroke is responsible for 9% of all 
deaths (Murray & Lopez, 1997). It claims 6.2 million lives each year and is the leading cause of 
adult disability. Following a stroke 15-30% of stroke survivors are permanently disabled and 
many require institutional care because of the extent of the damage (Lakhan et al., 2009). 
Depending on the brain area that is affected, patients can exhibit a variety of symptoms that 
include paralysis, loss of vision, deficits in speech and understanding, and difficulties with 
memory. Stroke is caused by the disruption of blood flow in the brain and can be ischemic or 
hemorrhagic in nature. Ischemic strokes are the most common type and account for 87% of all 
strokes (Thrift et al., 2001) and occur as a consequence of prolonged occlusion of a blood vessel 
by a thrombus or embolism (Frizzell, 2005) .  
Ischemic Cascade: 
The ischemic cascade is triggered following a stroke and can cause irreversible neuronal 
injury in the ischemic core within minutes of the onset (Dirnagl et al., 1999). This central core is 
characterized by severely compromised cerebral blood flow and is surrounded by a much larger 
volume of brain tissue, known as the penumbra. The penumbra refers to the area of the brain that 
is damaged, having impaired electrical activity but preserved cellular metabolism and viability 
(Astrup et al., 1981; Hakim, 1987; Kaufmann et al., 1999).  The tissue in the penumbra has a 
variable outcome and can be salvageable if cerebral blood flow can be restored within 6 to 8 
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hours (Wise et al., 1983; Baron et al., 1995; Marchal et al., 1996; Kaufmann et al., 1999).   The 
central goal of therapy in acute stroke is to target this area and preserve brain tissue that would 
reduce post-stroke disabilities.  
Glutamate-mediated excitotoxicity represents the major mechanism in the 
pathophysiology of stroke. Glutamate is the major excitatory neurotransmitter in the central 
nervous system and plays an important role in mediating developmental plasticity and growth, 
intracellular communication and learning and memory (Matute et al., 2002).  Excitotoxicity is 
caused by the pathological over-activation of  the glutamate receptors (Mattson, 2003).  The 
release of glutamate following ischemia activates metabotropic glutamate (mGluR) and 
ionotropic glutamate receptors (iGluR). 
Metabotropic receptors: mGluRs are G-protein coupled receptors and are divided into three 
groups. Group I mGluR agonists were shown to downregulate the excitatory amino acid 
transporter-1 (EAAT1) while Group II mGluR agonists upregulated its expression (Gegelashvili 
et al., 2000). Group II mGluR are present both pre- and post-synaptically and are also located on 
glial cells (Petralia et al., 1996). Both Groups II and III mGluRs are negatively coupled to cyclic 
AMP which is derived from ATP. Therefore, a loss of ATP during cerebral ischemia 
(Folbergrová et al., 1992)  will also lead to changes in mGluR activity and a loss of glutamate 
regulation (Hazell, 2007). 
Ionotropic receptors: There are three known types of iGluRs based on their different agonist 
specificities; the NMDA (N-methyl-D-aspartate) receptor, AMPA (α-Amino-3-hydroxy-5-
methyl-4- isoxazolepropionic acid) receptor and Kainate receptor. The AMPA and Kainate 
receptors mediate fast synaptic transmission and are permeable to Na+ and K+ and low 
concentrations of Ca2+ (Hollmann et al., 1991). NMDA receptors are more permeable to Ca2+ 
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and are voltage dependent as a result of ion channel blockade by extracellular Mg2+ (MacDermott 
et al., 1986). This makes their activation secondary to the activation of the AMPA and Kainate 
receptors that depolarize the neuron and the release of Mg2+ blockade (Lynch & Guttmann, 
2002). The iGluRs are the major mediators of excitotoxicity, more specifically, the NMDA 
receptors because of their high Ca2+ conductance and the voltage-dependent fluxes (Hazell, 
2007).  Studies have established that Ca2+ overload following iGluR overstimulation is key in 
glutamate-mediated toxicity. The removal of Ca2+ but not Na+ led to a decrease in neuronal death 
following glutamate treatment (Choi, 1987). Tymianski et al. (1993) demonstrated that the 
neurotoxicity of glutamate was primarily triggered by Ca2+ influx through NMDA receptor 
channels rather than non-NMDA receptors and voltage-sensitive Ca 2+channels. This was not due 
to its ability to trigger greater amounts of Ca2+. They hypothesized that it was a result of a 
physical co-localization of  NMDA receptors with Ca2+-dependent secondary processes that 
cause neuronal degeneration (Tymianski et al., 1993).  
Some of these downstream processes that ultimately result in cell death include the 
initiation of the arachidonic acid cascade (Dumuis et al., 1988; Lazarewicz et al., 1990; Sanfeliu 
et al., 1990) the activation of catabolic enzymes such as endonucleases,  proteases (Siman et al., 
1989) and  lipases (Farooqui & Horrocks, 1991). Ca2+ also increases the activity of nitric oxide 
synthase (Fleming et al., 1997) and the release of nitric oxide (Beckman, 1991; Dawson et al., 
1991) and causes the formation of reactive oxygen species (ROS) (Pellegrini-Giampietro et al., 
1990). ROS can cause damage through a direct oxidation of proteins, lipids and nucleic acids 
leading to the breakdown of the cell membrane, the cytoskeleton and the genomic DNA.  The 
accumulation of intracellular Ca2+ can also cause mitochondrial dysfunction and the activation of 
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cell signaling pathways such as the caspase cascade (Sugawara et al., 2002) and the p53 pathway 
(Trinei et al., 2002) that lead to apoptosis (Pradeep et al., 2012).  
Figure 1.1 summarizes the mentioned biochemical pathways in the ischemic cascade that 
ultimately result in cell death (Mattson et al., 2000). 
Astrocytes and glutamate transporters:  
The removal of glutamate from the extracellular space by excitatory amino acid 
transporters (EAATs)  is one of the main functions of astrocytes (Drejer et al., 1983), a process 
that is essential in maintaining the levels of this neurotransmitter within a normal range (Nicholls 
& Attwell, 1990; Hazell, 2007). There are five subtypes of Na+ dependent glutamate transporters 
in the brain, two of which (EAAT1and EAAT2) are predominantly localized in astrocytes 
(Danbolt et al., 1992) and provide major buffering of glutamate in brain (Danbolt, 2001).  
Glutamate transport in astrocytes is altered in response to a stroke. A number of 
processes contribute to excitotoxicity under cerebral ischemia. These include (1) a decrease in 
glutamate uptake as a consequence of EAAT1 and EAAT2 downregulation  (Rothstein et al., 
1996; Rao et al., 2001; Yeh et al., 2005) (2) glutamate efflux as a result of transporter reversal 
(Szatkowski et al., 1990; Longuemare & Swanson, 1995) that occurs when ATP decreases and 
suppresses of the Na+/K+ ATPase (Lees, 1991) after prolonged ischemia. This causes a loss of 
the ionic gradients necessary to drive the transporter function. (3) Enhanced glutamate release 
caused by the dysregulation of vesicular release (Hazell, 2007).  
Considering their important role in maintaining glutamate homeostasis, their involvement 
in excitotoxicity, and lack of understanding of their involvement in ischemia,  more emphasis is 
now being placed on astrocytes and their  roles in cerebral injury and neurodegenerative diseases 
(Maragakis & Rothstein, 2006).  
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Figure 1.1 Overview of the biochemical cascades that occur in response to ischemia 
Adapted from Mattson et al. (2000) 
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1.2 Treatments for ischemic stroke 
More than 1,000 drugs have been tested in various animal models, of these 114 
underwent clinical trials (Pérez de la Ossa & Davalos, 2007) that ultimately failed (Lakhan et al., 
2009). Consequently, recombinant tissue plasminogen activator (rt-PA) remains the only agent 
shown to improve stroke outcome. Rt-PA can effectively reduce neurological deficits and 
improve stoke outcome when administered within three hours after symptom onset (Lakhan et 
al., 2009). However, a majority of patients do not go to a hospital within these 3 hrs and thus 
cannot receive this treatment. Rt-PA is also associated with an increased incidence of 
symptomatic intracranial hemorrhage, which occurs in approximately 6% of patients (Furlan et 
al., 2003). The optimum treatment of cerebral focal ischemia remains one of the major 
challenges in clinical medicine. It’s been suggested that one of the major reasons for the failure 
of the clinical trials was an incomplete understanding of the mechanisms responsible for cell 
death during ischemia (Wang & Shuaib, 2007). Understanding and defining the brains own 
endogenous neuroprotective mechanisms that occur in ischemic tolerance has been suggested as 
a good way to unravel the molecular mechanisms and might improve therapeutic strategies for 
patients with stroke (Dirnagl et al., 2003; Schaller et al., 2003). 
Ischemic tolerance and ischemic preconditioning: 
Tolerance is a phenomenon in which any stimulus that is applied at a subtoxic level can 
activate protective mechanisms that can reduce the damage done by a subsequent, more severe 
exposure. This adaptive capability is fundamental in protecting living cells and allowing them to 
survive potentially recurrent stressors (Durukan & Tatlisumak, 2010). A solution to reducing 
ischemic brain damage could be derived from studying the mechanisms by which cells adapt to 
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an ischemic stress or ischemic preconditioning.  A preconditioning stimulus in the brain will 
initiate adaptive pathways in cells that will establish a latent cerebroprotective phenotype 
(Figure.1.2) that prepares the brain for an injurious ischemic event (Gidday, 2006) and promote 
an ischemic-tolerant phentotype characterized by less tissue damage. This phenomenon has been 
confirmed in various in vivo models of ischemia and in in vitro models of primary neurons. 
Additionally, it has been observed in humans in the form of a transient ischemic attack (TIA) 
(Wegener et al., 2004) which occurs as a short period of ischemia that does not form an infarct. 
Studying the molecular and regulatory pathways that participate in preconditioning has provided 
the opportunity to uncover endogenous neuroprotective mechanisms that can be utilized for the 
treatment of stroke patients.  
1.3 Protective Mechanisms that occur in ischemic tolerance 
1.3.1 Excitatory neurotransmitters and receptors: 
NMDA receptors: 
Preconditioning neurons with exogenous NMDA at subtoxic concentrations was 
sufficient to induce resistance against subsequent in vitro ischemia and glutamate-mediated 
excitotoxicity (Grabb & Choi, 1999; Tauskela et al., 2001; Jiang et al., 2003). Blocking the 
NMDA receptor with either MK-801, the non-competitive NMDA receptor antagonist, or 
LY202157 the competitive NMDA receptor antagonist, during preconditioning eliminated the 
ischemic tolerance in both in vivo and in vitro models (Bond et al., 1999). This implies that mild 
activation of the NMDA receptor plays a role in the protective effect of ischemic 
preconditioning. One mechanism by which this occurs is that the NMDA receptor mediates rapid  
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Adapted from Gidday (2006)  
Figure 1.1 Cerebroprotection by preconditioning. 
Ischemia- induced injurious responses (red arrows) lead to an injurious phenotype in the non-
preconditioned brain. However, a preconditioning stimulus promotes the induction of protective 
responses both pre- and post-ischemia that protect the brain against the injurious responses of 
ischemia and results in a tolerant phenotype.  
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adaptation of the voltage-dependent calcium influx. Gerbils subjected to ischemic 
preconditioning were able to regulate calcium levels and maintain them at concentrations that did 
not result in neuronal damage whereas non-tolerant gerbils showed an increase in calcium influx 
(Shimazaki et al., 1998). Another mechanism is through the rapid release of brain-derived 
neurotrophic factor (BDNF) following the activation of the NMDA receptor (Steiger & Hänggi, 
2007). Other key mediators that are involved in NMDA receptor-dependent neuroprotection 
glycogen synthase kinase 3 beta (GSK3β), phosphatidylinositol 3 (PI3)-kinase and include cyclic 
AMP responsive element binding protein (CREB) (Soriano et al., 2006; Steiger & Hänggi, 
2007). CREB is activated in response to elevated intracellular calcium caused by NMDA 
receptor activation (Hu et al., 1999). Phosphorylation of CREB is enhanced in the penumbra of 
preconditioned rats (Nakajima et al., 2002) and is implicated as an important player in NMDA 
receptor preconditioning  (Liu et al., 2009).  
AMPA receptors: 
 The role of the AMPA receptor in ischemic preconditioning is not well established and 
contradictory results exist (Durukan & Tatlisumak, 2010). Some studies have shown that the 
AMPA and kainate receptor blocker DNQX only partially attenuates ischemic tolerance (Bond et 
al., 1999; Gonzalez-Zulueta et al., 2000) in primary neurons while others have shown that the 
receptor blockade does not eliminate the preconditioning effect (Duszczyk et al., 2005).  
Calcium: 
The role of Ca2+ is not well definied in ischemic tolerance (Tauskela & Morley, 2004), 
however, the chelation of Ca2+ before and during oxygen and glucose deprivation (OGD) 
prevents ischemic tolerance in vitro (Raval et al., 2003; Durukan & Tatlisumak, 2010). 
10 
 
Adenosine and ATP-sensitive K+ (K+ATP) channels: 
 Adenosine is an endogenous neuroprotectant that can inhibit the release of excitatory 
neurotransmitters. During ischemia, adenosine is formed as a degradation product of ATP.  
Studies have demonstrated that adenosine A1 receptors are essential in preconditioning- induced 
protection in the brain (Heurteaux et al., 1995). The activation of A1 receptors leads to an 
inhibition of synaptic transmission, glutamate release and presynaptic calcium fluxes that would 
otherwise lead to cell damage and death. Ischemic preconditioning increased the A1 receptor in 
the rat hippocampus (Zhou et al., 2004). Adenosine A1 receptor antagonists attenuated or 
abolished the ischemic tolerance phenomenon in rats (Yoshida et al., 2004) and gerbils (Hiraide 
et al., 2001).  
 Plasma membrane KATP channels are found widely throughout the brain (Rodrigo & 
Standen, 2005) and their activation also plays a role in brain ischemic preconditioning. 
Treatment with KATP channel antagonists abolished ischemic tolerance (Reshef et al., 2000) and 
also canceled the protective effect of adenosine or the use of an A1 receptor agonist (Hiraide et 
al., 2001).  On the other hand, a KATP channel agonist induced ischemic tolerance (Auchampach 
et al., 1992; Gross & Auchampach, 1992; Yao & Gross, 1994).  
Excitatory amino acid transporters: 
Changes in EAATs density can contribute to the adaptive changes that occur during 
ischemic tolerance. An upregulation of EAATs could be protective by increasing the efficiency 
of extracellular glutamate removal (Obrenovitch, 2008).  However, a downregulation can also be 
beneficial when ischemia is severe enough to induce anoxic depolarization (Jabaudon et al., 
2000) by reducing glutamate efflux caused by reversed uptake (Rossi et al., 2000). Both in vivo 
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and in vitro studies have provided contradictory results for the effect of preconditioning on 
EAATs. Ischemic preconditioning in an in vivo stroke model in rats  led to an upregulation of 
EAAT2 and EAAT3 but had no effect on EAAT1 expression (Cimarosti et al., 2005; Pradillo et 
al., 2006).  Another study, also in rats, showed that preconditioning downregulated both EAAT1 
and EAAT2 (Douen et al., 2000). EAAT2 and EAAT3 were upregulated in primary cortical 
neurons that were subjected to sublethal oxygen-glucose deprivation (OGD). The preconditioned 
neurons also had increased glutamate uptake (Romera et al., 2004). Ischemic preconditioning in 
a neuron/astrocyte co-culture in different studies showed a downregulation of the EAAT2 
(Kosugi et al., 2005; Yamada et al., 2006). 
1.3.2 Mitochondria function 
The reperfusion period following a stroke in which the blood flow is restored, 
significantly contributes to injury that occurs. Various studies have shown that mitochondria 
dysfunction plays a role in this mechanism of injury. Dave et. al observed that mitochondrial 
function after brain ischemia was maintained in the rat hippocampus by ischemic 
preconditioning. They show that preconditioning restored the deficits in complex I-IV 
respiration. It also improves respiration (Dave et al., 2008), oxidative phosphorylation (Dave et 
al., 2001) and allows mitochondria to be more resistant to depolarization (Cho et al., 2005; Zhou 
et al., 2012). Since mitochondria are the main source of ROS, a preservation of mitochondrial 
function would reduce ROS generation. An interesting study by Bugger et. al showed that 
mitochondria that were isolated from an atrophied heart was more resistant to ischemia than a 
normotrophic heart (Bugger et al., 2006). Since atrophied hearts are characterized by an increase 
in ROS (Muller et al., 2007), that previous exposure to ROS could be the reason for the 
protection observed after the ischemia.  
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1.3.3 Heat Shock Response and protein degradation 
Heat shock proteins (HSPs) 
HSPs are molecular chaperones that assist in the folding of newly synthesized proteins. 
They are also among the proteins that are synthesized during ischemia when most proteins 
synthesis is inhibited, suggesting they could have an important role in maintaining cell viability 
(Liu et al., 2009). HSPs are expressed both constitutively or they can be inducible under 
conditions of stress. Inducible HSPs contribute to cytoprotection by preventing protein 
denaturation and improper aggregation (Franklin et al., 2005). In particular, the role of 72-kDa 
HSPs, or HSP70 has been well characterized and studied extensively with regard to ischemic 
preconditioning (Obrenovitch, 2008). HSP70 was increased in the hippocampus of gerbils 
exposed to a brief period of ischemia and was correlated with an increase in neuronal viability. 
(Kirino et al., 1991). A rat in vivo model of ischemic preconditioning also resulted in increased 
HSP70 protein expression (Liu et al., 1993; Nishi et al., 1993). HSP70 suppression in gerbils 2 
hrs before or 3 hrs after the preconditioning stimulus inhibited the induction of ischemic 
tolerance in the hippocampus (Nakata et al., 1993; Obrenovitch, 2008). 
The mechanisms of HSP70-mediated cytoprotection are not only limited to its important 
role in protein folding and transport. Mutated HSP70s that were able to bind to denatured 
proteins but not fold them were still protective in both in vivo and in vitro models of ischemia 
(Sun et al., 2006).  The protective actions were attributed to their role in maintaining 
mitochondrial function in terms of improving respiration, reduced formation of ROS and 
inhibiting changes in mitochondrial membrane potential (Ouyang et al., 2006). HSP70 is also 
capable of binding and sequestering apoptosis protease activating factor-1 (Apaf-1 ) and 
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preventing the formation of the apoptosome (Saleh et al., 2000).  Deleting the HSP70 gene 
increased the infarct volume after ischemia through enhanced apoptosis as a result of increased 
cytochrome c release into the cytoplasm  and subsequent caspase-3 activation (Lee et al., 2004) 
(Liu et al., 2009).  
Ubiquitin Proteasome System (UPS) 
The UPS represents the main pathway responsible for the degradation of abnormal or 
unwanted proteins. Numerous neuropathological diseases, including stroke, have been implicated 
with an inability of the proteasome to cope with an overproduction of abnormal proteins. When 
proteins are damaged or are unfolded they tend to form aggregates that are toxic to cells (Taylor 
et al., 2002; Dobson, 2003).  Neuronal death following brain ischemia does not occur 
immediately but takes place during reperfusion in which cerebral blood flow gradually recovers 
(Kirino, 1982; Kirino et al., 1984; Nitatori et al., 1995). Previous studies have indicated that 
during this period there is an accumulation of unfolded proteins and ubi-protein aggregates in the 
vulnerable ischemic neurons (Hu et al., 2001; Liu et al., 2005a; Liu et al., 2005b; Ge et al., 
2007) that lead to their death. However, preconditioning neurons with a short period of sublethal 
ischemia resulted in decreased protein aggregation after ischemia (Liu et al., 2005a). 
1.3.4 Hypoxia-inducible factor (HIF-1α) 
Among the transcription factors that are regulated by hypoxia, HIF isoforms, more 
specifically HIF-1, have gained the most experimental support, (Durukan & Tatlisumak, 2010). 
HIF-1 proteins are the primary mechanism by which cells respond to hypoxia (Wang & 
Semenza, 1995)  and have been shown to increase during conditions of ischemic tolerance and 
preconditioning (Bergeron et al., 2000; Bernaudin et al., 2002).  Hypoxic preconditioning can be 
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mimicked using pharmacological activators of HIF such as deferoxamine or cobalt chloride 
(Bergeron et al., 2000). The binding of HIF-1α to HIF-1β in the nucleus results in the induction 
of HIF target genes. Several of these genes contribute to protection from ischemia by improving 
cellular metabolism, vascularization, proliferation and glucose metabolism (Sharp et al., 2004; 
Durukan & Tatlisumak, 2010). Studies performed on the heart have shown the protective effect 
of ischemic preconditioning was lost in mice that are heterozygous for the HIF-1α knockout 
allele (Cai et al., 2003) when HIF-1α was inhibited using siRNA (Eckle et al., 2008). 
1.3.5 Reactive oxygen species and defense mechanisms against oxidative stress 
ROS are recognized as important mediators of the ischemic/reperfusion injury (Zweier & 
Talukder, 2006).  However, recent studies suggest that oxygen free radicals can trigger signal 
transduction pathways in ischemic preconditioning process (Wiegand et al., 1999; Wada et al., 
2001). The free radical scavenger, N-t-butyl-alpha-phenylnitrone (PBN) abolished the protective 
action of hypoxia preconditioning and the hydroxyl radical (·OH) was involved in the 
development of the hypoxic preconditioning phenomenon (Rauca et al., 2000). Murry et al., 
(1988) showed that administration of oxygen radical scavengers during the first reperfusion 
period attenuated the beneficial effect of preconditioning on reducing infarct size in the heart. 
They proposed that a brief ischemic episode that leads to the generation of a low amount of 
oxygen free radicals which is not sufficient to cause cell death can modify cellular activity and 
induce preconditioning effects (Murry et al., 1988).  
Under normal conditions, the first line of defense triggered in response to an oxidant 
insult is the production of antioxidants that can prevent damage by scavenging the free radicals. 
However, during ischemia oxidative stress is not only due to an increased generation of ROS but 
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also because of the reduction in the levels of antioxidants due to increased consumption or 
changes in the expression and activities of antioxidant enzymes that include superoxide 
dismutase (SOD), catalase and glutathione peroxidase (Lyrer et al., 1991; Mahadik et al., 1993; 
Love, 1999; Lewen et al., 2000).  Another neuroprotective mechanism induced by ischemic 
preconditioning is the upregulation of antioxidants that reduce oxidative stress caused by 
ischemia and reperfusion. These include antioxidant enzymes such as SOD (Yuan et al., 2010) 
and low molecular weight antioxidants such as ascorbic acid (Glantz et al., 2005). Transgenic 
mice that over-express SOD were resistant to injury following cerebral ischemia and reperfusion 
(Yang et al., 1994). 
1.3.6 Glial Ischemic tolerance 
Astrocytes extensively communicate with neurons which they ensheath. Changes in the 
brain environment are effectively sensed by astrocytes to which they are able to respond 
immediately at a genomic (e.g., trophic factors) and non-genomic level (e.g., uptake of 
glutamate) (Trendelenburg & Dirnagl, 2005). The response of astrocytes to a preconditioning 
stimulus is crucial to the foundation of the overall cerebroprotective phenotype (Gidday, 2006).  
The supportive function of astrocytes is not limited to their own protection but to neurons as well 
which they are in intimate contact with. Astrocytes promote ischemic resistance of neighboring 
neurons through various mechanisms which include improved ionic buffering and transferring 
energy substrates and intermediates for the de novo synthesis of the neurotransmitters glutamate 
and gamma-Aminobutyric acid (GABA). Astrocytes are the main source of the hormone 
erythropoietin (EPO) and are major contributors to the antioxidant defense of the brain and play 
a central role free radical and reactive metal scavenging. The generation of anti-inflammatory 
cytokines, heat shock proteins and trophic factors such as Transforming Growth Factor-β 
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(TGFβ), Brain-Derived Neurotrophic Factor (BDNF) and the Glial Cell Line-Derived 
Neurotrophic Factor (GDNF) by preconditioned astrocytes contribute to ischemic tolerance 
(Gidday, 2006). 
Activation of astrocytes and microglia/macrophages can be triggered in response to 
ischemia. Morphologically, they adopt a more immature phenotype (Kajihara et al., 2001) and 
undergo morphological changes where they extend their processes and thus contribute to brain 
tissue damage by causing regeneration failure. Studies have shown however, that ischemic 
preconditioning can attenuate the activation of astrocytes and microglia following cerebral 
ischemia (Kato et al., 1994; Rosenzweig et al., 2004) through the repression of NF-κB mediated 
transcription of inflammatory mediators (Ginis et al., 2002).  
Further research is needed to understand whether and how astrocyte protection can be 
therapeutically utilized after cerebral ischemia. This could be either done by boosting astrocytic 
neuroprotection, or by delivering therapeutics that mimic astrocyte derived neuroprotectants. 
1.4 Potential clinical applications 
1.4.1 Ischemic preconditioning 
A study by Chan et al. (2005) evaluated the effects of temporary artery occlusion on brain 
tissue gases and acidity during a cerebral aneurysm clipping to produce an ischemic 
preconditioning model.  A multiparameter catheter was inserted to determine oxygen and carbon 
dioxide tension, and the pH levels in tissue that was at risk of ischemic injury during the 
temporary artery occlusion. Patients with aneurysmal subarachnoid hemorrhage were used for 
the study. The preconditioning group was subjected to an initial 2 min occlusion of a proximal 
artery followed by 30 min of reperfusion before undergoing the cerebral artery occlusion for the 
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clipping of the aneurysm. The results demonstrated that the preconditioned group showed a 
significant decrease in the decline of oxygen tension and pH compared to the control, untreated 
group. This attenuation in tissue hypoxia suggests that a brief occlusion of the proximal artery 
provides brain protection following the subsequent artery occlusion (Chan et al., 2005).  
Another study by Wegener et al. (2004) investigated whether transient ischemic attacks 
(TIAs) can raise the threshold of brain vulnerability and induce tolerance in response to a 
subsequent stroke. They concluded that the initial lesions tended to be smaller and final infarct 
volumes were also drastically reduced in patients with a history of TIA. These patients also 
exhibited milder clinical deficits (Wegener et al., 2004). Other reports show that TIAs appear to 
be neuroprotective when they were recent, when multiple attacks occurred (not more than three) 
and when they were of a shorter duration (less than 20 min) (Moncayo et al., 2000).  Elderly 
patients that were over the age of 65 did not benefit from TIAs (Della Morte et al., 2008). This 
protective effect of TIAs on reducing infarct size and facilitating thrombolysis (Wegener et al., 
2004; Schaller, 2005) suggests the existence of endogenous neuroprotection in the human brain 
(Dezfulian et al., 2013).   
1.4.2 Ischemic postconditioning  
Ischemic postconditioning refers to ischemic tolerance that occurs as a result of an 
interruption of blood flow during the reperfusion period. These short bursts of ischemia that were 
performed at the time of reperfusion lead to a decrease in the volume of the damaged tissue 
(Lehotský et al., 2009). Similar to ischemic preconditioning, postconditioning was initially 
demonstrated in the heart in a cat model of regional cardiac ischemia. The results demonstrated 
that intermittent reperfusion prevented reperfusion-induced ventricular fibrillation and was as 
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effective as ischemic preconditioning (Na et al., 1996). This was further confirmed  as a 
protective treatment in the heart (Zhao et al., 2003; Galagudza et al., 2004; Kin et al., 2004), and 
then demonstrated in other organs that include the liver (Sun et al., 2004), kidney (Liu et al., 
2007), muscles (McAllister et al., 2008), skin (Moon et al., 2008) and the intestinal mucosa 
(Santos et al., 2008). Brain  Ischemic postconditioning with a series of interruptions of 
reperfusion also proved to be protective and increased neuronal survival rate in an in vivo model 
of focal ischemia (Zhao et al., 2006; Xing et al., 2008) and  global cerebral ischemia (Pateliya et 
al., 2008; Wang et al., 2008).  
Little is known about the mechanisms of ischemic postconditioning as it is still a novel 
neuroprotective approach. There is evidence that ischemic postconditioning can improve cerebral 
blood distribution by reducing the effects of hyperemia and the resulting hypoperfusion (Wang et 
al., 2008).  Loukogeorgakis et. al. (2006) observed that postconditioning can reduce tissue injury 
when applied at the onset of reperfusion  (Loukogeorgakis et al., 2006). This provides a narrow 
therapeutic window of opportunity and would be challenging in a clinical setting where the 
interruption of reperfusion would not be performed at the end of ischemia (Lehotský et al., 
2009). However, other studies using a delayed postconditioning paradigm that occurred 3-6 
hours after focal ischemia (Ren et al., 2008) or 48 hrs after ischemia (Burda et al., 2006)  
reduced infarct size. Thus, targeting neuronal death that occurs in a delayed manner broadens the 
potential therapeutic window for inhibiting processes that lead to apoptosis.  
1.4.3 Future Clinical Considerations 
The delivery of brief ischemia in either a preconditioning or postconditioning paradigm 
can be technically challenging and there is still much controversy over whether it is possible to 
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be used as a therapeutic measure to promote neuronal survival in the brain. Even a very short 
period is bound to have a harmful effect and thus ethical and safety concerns still exist. There 
was some evidence of a therapeutic benefit in clinical trials of ischemic preconditioning in which 
patients that were on cardio-pulmonary bypass were subjected to aortic clamping before the 
procedure (Hausenloy & Yellon, 2009). The heart however, is less sensitive than the brain and 
can better tolerate such an insult without cell death (Dezfulian et al., 2013). A study by 
Oppenheim et al.(2006) determined that a long-tern MRI follow up of TIA patients revealed 
infarcts and lesions  in attacks that were previously thought of as being harmless (Oppenheim et 
al., 2006). Hallmarks of injury were also observed in experimental models with a longer follow-
up duration and when more sensitive detection methods were utilized (Sommer, 2008). In other 
experimental animal models, different combinations of ischemic preconditioning were not 
protective and caused more severe injuries following a subsequent ischemic episode (Tomida et 
al., 1987). Different human populations also exhibit various levels of sensitivities. For instance, 
geriatrics, which would be the target population, or females tend to be less tolerant to injury and 
might not benefit from these protective effects. Furthermore, different pre-existing conditions or 
medications used by patients will also have to be put into consideration (Lehotský et al., 2009). 
Therefore, identifying a safer stimulus to induce tolerance would be both more practical and 
effective.  
1.4.4 Stimulus Inducing Tolerance 
Different activating mechanisms and paradigms have been shown to induce ischemic 
tolerance (Table 1.1).  Brief periods of global ischemia (Kitagawa et al., 1991), focal ischemia 
(Stagliano et al., 1999) or cerebral hypoxia represent the prototypical preconditioning stimuli 
(Lehotský et al., 2009). However, preconditioning can be induced through exposure to  
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Table 1.1 Various inducing stimuli leading to ischemic tolerance in different in vivo and in 
vitro models.  
Adapted from Lehotsky et al (2012) 
 
Inducing Stimuli Experimental models 
Sublethal preischemia G, R, M, C 
Sublethal postischemia G, R, M 
Spreading depression/excitoxicity R, M 
Remote ischemia R, M 
pH/ion imbalance R, M, C 
Oxidative/nitrosative stress G, R, M, C 
Other factors (hormones, toxins) G, R, M, C 
Lipopolysaccharides R 
Immunization/inflammatory cytokines G, R, M, C 
Hypoxia or HIF modifiers G, R, M, C 
Hypoperfusion G, R, M  
Hypoglycemia/metabolic inhibitors G, R, M, C 
Hyper/Hypothermia G, R, C 
Exercise G, R, M  
Erythropoietin G, R, M  
Epilepsy M 
Anesthetics R, M 
 
       G, gerbil; R, rat; M, mouse; C, cell culture model; HIF, hypoxia inducible factor 
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endogenous or exogenous stimuli such as hypoperfusion (Sharp & Bernaudin, 2004), hyperoxia 
or oxidative/nitrosative stress, cortical spreading depression (Kobayashi et al., 1995), and hyper 
or hypothermia  and heat shock (Nishio et al., 2000).  Pharmacological agents such as metabolic 
inhibitors, lipopolysaccharides and inflammatory cytokines or natural regulators such as EPO or 
other hormones can also induce ischemic tolerance (Lehotský et al., 2009). The phenomenon in 
which a noxious stimulus can induce cellular tolerance to a subsequent stimulus that is different 
in nature from the first is referred to as cross-tolerance.  
1.5 In Summary 
Our knowledge of the complex pathophysiology and the mechanisms of ischemic 
preconditioning remain insufficient to be able to translate to a clinical setting.  Defining key 
proteins that proved to be protective can potentially be used as tolerance producing drugs. HIF-
1α is the major regulator of oxygen homeostasis and functions to induce a wide array of 
transcripts. HIF-1’s downstream targets mediate a number of cellular mechanisms that can 
facilitate cellular adaptation to hypoxia and promote survival. Even without preconditioning, 
brain cells naturally respond to hypoxia by triggering a host of defenses to counter cell injury and 
death (Sapolsky, 2001); the most critical of these responses being the stabilization of HIF-1α. 
HIF-1 is part of the fundamental endogenous protective responses that occur after stroke that can 
be innate but is also adaptive following a preconditioning stimulus. We have sought to 
understand the mechanisms of HIF-1 stability and degradation and to determine its use as a 
potential therapy for the treatment of stroke.  
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Ischemia initiates a complicated biochemical cascade of events that triggers cell death. 
These events include the release of glutamate, excitotoxicity induced by over-activation of 
glutamate receptors, Ca2+ influx, mitochondrial dysfunction, ROS production, activation of 
enzymes, inflammation and apoptosis (Figure 1.1). The modulation of any of these molecular 
targets within the ischemic cascade can induce protection. In our studies, we chose to purse the 
effects of glutamate as glutamate-induced toxicity is the major cause for the initiation and 
maintenance of this cascade. Moreover, excitatory neurotransmitter, receptors and transporters 
are important contributors to ischemic preconditioning. We examined the effects of glutamate 
toxicity on the viability of astrocytes exposed to hypoxia and the role that HIF-1 plays under 
these conditions.  We also aimed to better understand the mechanisms of tolerance induced by 
adaptation to chronic levels of glutamate. Taking advantage of these mechanisms may lead to the 
development of safer therapeutic agents and more feasible approaches to treat ischemic strokes. 
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Chapter 2: A comparative study: effects of proteasome and hydroxylation 
inhibitions on hypoxia inducible factor 1α degradation in cerebral ischemia 
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2.1 ABSTRACT 
Hypoxia inducible factor-1 (HIF-1) is a key regulator in hypoxia and can determine the 
fate of brain cells during ischemia.  However, the mechanism of HIF-1 regulation is still not fully 
understood in ischemic brains.  We previously demonstrated that the presence of glucose 
maintained the level of HIF-1α protein, the regulatable subunit of HIF-1, in ischemic neurons.  In 
this study, we tested a hypothesis that both the 26S and the 20S proteasomal pathway were 
involved in HIF-1α degradation under ischemic conditions due to the action of reactive oxygen 
species (ROS).  We observed that superoxide anion radical increased 20S but decreased 26S 
proteasomal activity in SH-SY5Y cells.  In the concentration range of 0-200 µM, H2O2 elevated 
20S proteasomal activity while it only increased 26S activity at concentrations less than 100 µM.  
Pre-treatments of the SOD mimic and catalase decreased both 20S and 26S proteasomal activity 
in SH-SY5Y cells exposed to oxygen and glucose deprivation (OGD). We also demonstrated that 
proteasome inhibitors increased HIF-1α stabilization and cell viability and were more effective 
than prolyl hydroxylase inhibitors, which inhibit HIF-1a hydroxylation and thus suppress HIF-1α 
degradation through 26S proteasomal pathway, indicating the involvement of 20S in the HIF-1α 
degradation. Furthermore, the administration of the proteasome inhibitor, epoxomicin, to mice 
subjected to a mouse model of middle cerebral artery occlusion resulted in a reduction in infarct 
size compared to the untreated animals. Overall, our results indicate that proteasomal inhibition 
promotes HIF-1α stabilization during ischemia and has a protective effect on neurons in reducing 
ischemia- induced cytotoxicity. 
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2.2 INTRODUCTION 
Hypoxia inducible factor 1 (HIF-1), a transcription factor, is considered to be the most 
critical factor involved in the cellular response to hypoxia. This is mainly due to its regulation of 
1-2% of human genes that play important roles in cellular adaptation to low oxygen (Mazure et 
al., 2004). HIF-1 is a heterodimeric protein formed by a continuously expressed subunit HIF-1β 
and an oxygen regulated subunit HIF-1α (Wang et al., 1995a). Under normal oxygen levels, 
HIF-1α is degraded through the ubiquitin-dependent proteasomal (26S) pathway, which requires 
the oxygen for prolyl hydroxylases (PHD) to hydroxylate the protein that is recognized by Von 
Hippel-Lindau tumor suppressor (pVHL), an E3 ubiquitin ligase.  During hypoxia, HIF-1α is 
stabilized in cells due to reduced hydroxylation resulting from an inactivation of the hydroxylase 
activities. We and others have shown that low oxygen does not increase the level of HIF-1a 
protein in cells exposed to oxidative stress such as in hypoxic neurons in the absence of glucose 
(Guo et al., 2008) The mechanism of low expression of HIF-1a in these conditions remains 
unclear. 
  The proteasomal proteolytic pathways are the main mechanisms responsible for the 
degradation of abnormal or unwanted proteins, which contain 26S and 20S proteasomal 
pathways.  The 26S proteasome is the most abundant form and is composed of a 20S catalytic 
core and two regulatory 19S caps (Coux et al., 1996). In order for a protein to be targeted to the 
26S proteasome, it requires a polyubiquitin tail which can be detected by the 19S for subsequent 
processing and unfolding. The 20S proteasome complex can exist on its own and unlike the 26S 
proteasome it does not target ubiquitinated proteins but may act on oxidized proteins (Coux et 
al., 1996).  Although both the 26S and 20S can degrade oxidized proteins, many studies have 
determined that the contribution of the 20S is significantly higher (Davies, 2001; Breusing & 
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Grune, 2008; Jung & Grune, 2008) ). Since HIF-1α contains residues with redox properties such 
as cysteine and methionine, it is an oxidizable protein (LE, 1996; Huang et al., 1998b). This 
potentially makes HIF-1α a target for degradation by the 20S proteasome in an oxidizing 
environment. Although they do not increase pVHL binding  or ubiquitination activities (Jahngen-
Hodge et al., 1997), ROS might activate prolyl hydroxylase under hypoxia and promote 26S 
proteasomal degradation pathways by restoring the hydroxylation (Haddad, 2002; Callapina et 
al., 2005). 
Ischemia is characterized by an increase in ROS formation.   We hypothesized that 
reactive oxygen species (ROS) play a role in HIF-1α degradation during ischemia through 
activation of not only the ubiquitin-dependent (26S) but also the ubiquitin- independent (20S) 
proteasomal pathways. To test the hypothesis, we assessed effects of ROS and ischemia on the 
26S and 20S proteasomal activities, evaluated the contribution of the proteasomal pathways to 
HIF-1α degradation during hypoxia, and determined the effect of HIF stabilization through 
proteasomal inhibition on neuronal viability and brain damage in an in vitro and in vivo ischemia 
model. Our results demonstrated that the 20S proteasomal activity was increased by ROS and 
following ischemia. Furthermore, we indicate a role of the 20S in HIF-1α degradation and that 
unlike solely inhibiting PHDs, a combined treatment of PHD and proteasome inhibitors is more 
effective in stabilizing HIF-1α.   
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2.3 MATERIALS AND METHODS 
2.3.1 Culture of SH-SY5Y cells and primary cortical neurons 
SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% fetal bovine serum (FBS) and antibiotics (penicillin-streptomycin 1:100) at 37 °C in a 
humidified incubator gassed with 95% air and 5% CO2. Medium was changed to DMEM without 
FBS and without antibiotics at 80% confluence.  Cells were then incubated at 37 °C in a 
humidified hypoxia chamber (Coy laboratory products) with 1% O2, 5% CO2 and balance N2 for 
0, 1, 4, or 12  hours (H). 
Primary neurons were prepared from the cortical tissue of Sprague–Dawley rat (Charles 
River Laboratories) brains at embryonic day 16 [E16] to E18. The tissues were washed with 
Hanks Balanced Salt Solutions (HBSS) and trypsinized for 25 minutes (min) at 37°C. The tissues 
were then dissociated using a fire polished glass pipette in Dulbecco's Modified Eagle Medium 
(DMEM) and 10% Fetal Bovine Serum (FBS) transferred into 25 cm2 flasks in starter medium 
(DMEM and 10% FBS). After 24 hrs, the medium was replaced by culture medium consisting of 
2 mM glutamine and the B27 supplement in Neurobasal media (Gibco). Experiments were 
conducted 10-12 days following dissection.  The University of Kansas Institutional Animal Care 
and Use Committee approved all procedures. 
2.3.2 Assessment of proteasomal activities 
Cells were treated with KO2 at concentrations of 5, 10, 20 and 50 μM, and H2O2 at 10, 
50,100 and 200 μM in DMEM for 3 hrs. Proteasomal activity was measured as described 
previously (Fekete et al., 2005). Cells were washed with phosphate buffered saline (pH 7.4) and 
then lysed by 2 freeze-thaw cycles in lysis buffer (25 mM HEPES (pH 7.8), 0.25 M sucrose, 
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10mM MgCl2 1 mM EDTA and 1 mM dithiothreitol (DTT)). The lysates were centrifuged at 
11,000 RPM at 4°C for 30 min. 10 μg of cell lysate proteins was incubated with 100 μL of 
proteasome activity assay buffer. The first assay buffer for evaluation of the 26S proteasome 
function consisted of 50 mM Tris (pH 7.4), 5mM MgCl2, 2 mM DTT, 2 mM ATP and the 
fluorogenic substrate Suc-LLVY-AMC (80 μM in 1% DMSO, Sigma-Aldrich). The second 
buffer for determining 20S proteasome function contained 20 mM HEPES (pH 7.8), 0.5 mM 
EDTA, 0.03% SDS and 80 μM Suc-LLVY-AMC. The assay monitors the hydrolysis of Suc-
LLVY-AMC into AMC (7-amino-4-methly-coumarin) which is then detected with a 
fluorescence plate reader at ex 380 nm and em 440 nm (24). 
2.3.3 In vitro protein degradation assays 
SH-SY5Y cells were exposed to 1% oxygen for 6 hours.  Precipitated HIF-1α protein 
with or without oxidation by H2O2 were incubated with 20S proteasome (Boston Biochem) to 
determine the proteasome’s ability to degrade the HIF-1α.  To be able to determine the 26S 
proteasome’s activity, the precipitated HIF-1α was incubated with cytosol fraction from SH-
SY5Y cells and the 26S proteasome (Boston Biochem).  After HIF-1α was incubated with the 
proteasome for 1 and 3 hrs, western blotting and ELISA assay were carried out to determine the 
level of HIF-1α.  MG-132 was used to confirm that the degradation was in fact the result of 
proteasome activity. 
2.3.4 Effect of 20S on HIF-1α under hypoxic conditions 
  To detect the effect of 20S on HIF-1α, proteasome inhibitors MG132 (10 µM, 25 µM, 50 
µM) or epoxomicin (2 µM, 4 µM, 8 µM)(Drexler, 1997; Salceda & Caro, 1997; An et al., 1998; 
Lee & Goldberg, 1998; Adams et al., 1999; Meng et al., 1999b; Zhang et al., 1999; Grune et al., 
2002; Zhou et al., 2006) were added in DMEM for 1 hr, and the then cells were treated under 
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hypoxic conditions for 3 hrs.  After treatments, the cells were collected for HIF-1α protein 
expression by western blotting and ELISA. 
2.3.5 Ischemia model 
In vitro: Neurons were incubated in 1% O2/ 5%CO2 (balanced with N2) at 37°C for 1 hr 
in glucose-free medium. Control experiments were conducted at 21% O2/ 5%CO2 with medium 
containing glucose (Goldberg & Choi, 1993). Neuronal viability was assessed using the MTT (3-
(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) assay kit (Invitrogen) as described 
previously (Mosmann, 1983). 
In vivo: Brain ischemia was induced using the well-established Middle Cerebral Artery 
Occlusion (MCAO) model in mice (Clark et al., 1997). ). Anesthesia for the mice was induced 
with 3% isoflurane and oxygen and maintained with 1.5% isoflurane, or to desired anesthetic 
effect, throughout the procedure. Buprenorphine was used as the analgesic and was injected pre-
operatively at 0.05 mg/kg.  20-25 g C57/Bl/6 male mice were subjected to MCAO followed by a 
24 hr period of reperfusion.  TTC (2,3,5-triphenyltetrazolium chloride monohydrate) staining 
was used to assess brain damage (Ito et al., 1997). Brain edema volume (Vedema) was measured 
from the coronal sections that were stained by TTC by determining the volumes of both the 
ipsilateral (affected) hemisphere (VIpsi) and the contralateral hemisphere (Vcontra) and using the 
equation: Vedema =Vcontra - VIpsi (Yan et al., 2011). 
2.3.6 Proteasome inhibition and PHD inhibition  
Primary cortical neurons were pre-treated for 60 min with the proteasome inhibitors MG-
132 (Boston Biochem) (10, 40 and 80 μM) and Epoxomicin (Boston Biochem) (8 μM). Prolyl 
hydroxylases were inhibited with 2 mM dimethyloxalylglycine (DMOG). For in vivo studies 
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DMOG (50 mg/kg/0.1cc, i.p.) and/or Epox (1.1 mg/kg/0.1cc), i.p.) in DMSO were administered 
to mice 24 hrs before MCAO. 
2.3.7 Immunoblot analysis  
Neurons were lysed in 200 µL RIPA buffer (ThermoScientific) containing the protease 
inhibitor cocktail (Thermo Scientific) and scraped using a cell lifter (Biologix Research 
Company). The lysates were centrifuged at 12,000 RPM for 10 min at 4°C and the protein 
concentration of the supernatants was determined using a protein assay kit (Bio-Rad). Proteins 
were separated by SDS–PAGE and the separated proteins were transferred to a nitrocellulose 
membrane (BIO-RAD). After being blocked with 5% nonfat milk in Tris-buffered Saline with 
Tween (TBST), the membrane was incubated with the HIF-1α (1-1000; BD transduction 
laboratories) or the hydroxyl-HIF (1-1000; Novus) primary antibody overnight at 4°C and the 
secondary antibody (1-3000 ; goat anti mouse or goat anti rabbit; Santa Cruz) for 1 hr at RT. 
Western blots were quantified using ImageJ software and protein levels were normalized to β-
actin.  
2.3.8 Statistical analysis 
Data are presented as means ± SD from a minimum of three independent experiments. 
One-way ANOVA and the Student’s t-test were used for overall significance. Differences of 
p<0.05 were considered statistically significant.  Image-Pro Plus 5.1 (Media Cybernetics), 
ImageJ, and Excel were used for data analyses.  
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2.4 RESULTS 
2.4.1 ROS alter proteasomal activity in hypoxic SH-SY5Y cells 
We first evaluated the effect of ROS on proteasomal activity in SH-SY5Y cells.  As 
shown in Fig. 2.1, ROS had a differential effect on 20S and 26S proteasomal activities.  KO2 
generating superoxide anion radical dramatically increased 20S activity at 5, 10, and 20 μM 
whereas it decreased 26S activity.  H2O2 in the concentration range of 0-200 µM significantly 
elevated 20S activity.  In contrast, H2O2 increased 26S activity only at the lower concentrations 
of 10 and 50 μM.  The results indicate that both 20S and 26S activities can be inhib ited or 
activated by ROS depending on the concentration of ROS and that there is a wider concentration 
range of O2
- or H2O2 that can increase 20S activity versus the 26S activity. 
2.4.2 20S proteasome can degrade HIF-1α under hypoxia  
We investigated the effect of 20S on HIF-1α at elevated ROS conditions in a biochemical 
system. HIF-1α protein was prepared by incubating the cell extracts with anti-HIF-1α antibody 
and protein A-sepharose beads. Precipitated HIF-1α protein with or without oxidation was 
incubated with either the 26S or 20S proteasome for 1 or 3 hrs, followed by immunoblotting for 
HIF-1α. As shown in Fig. 2.2, H2O2 treatment alone or in the presence of 26S proteasome had no 
effect on the level of HIF-1α protein.  The level of HIF-1α protein was decreased in the presence 
of 20S proteasome for 1 hr and there was a further decrease after 3 hrs.  In the presence of 
ubiquitin, 26S proteasome caused HIF-1α degradation whereas 20S proteasome had no effect on 
the level of HIF-1α. 
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Figure 2.1. Effect of oxidative stress on proteasomal activity. Effect of potassium superoxide 
(KO2) and hydrogen peroxide (H202) on the activities of the 26S and 20S proteasome in SY5Y 
cells exposed to hypoxia for 3 hrs.   
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Figure. 2.2. HIF-1α degradation by the 20S proteasome under hypoxia. Immunoblotting for 
HIF-1α after the HIF-1α protein-beads were incubated with either the 26S or 20S proteasome for 
1 and 3 hrs with the addition of H2O2 or ubiquitin.   
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2.4.3 In vitro ischemia upregulates proteasomal activity in neurons   
Next, we determined whether ischemia could have the same effect on proteasomal 
activity in neurons. Oxygen-glucose deprivation (OGD) was used as an in vitro ischemia model 
which mimics the loss of oxygen and glucose that occur in a stroke when blow flow is blocked. 
Primary cortical neurons were exposed to OGD for 30, 60 and 90 min and then the activities of 
the 26S and 20S proteasome were assessed and compared to neurons at control conditions.  
Following OGD treatment, there was a mild increase in 26S activity; however, it was not 
statistically significant (Table 2.1). On the other hand, 20S activity was significantly increased 
after 30 or 60 min exposure to OGD. The activity began to decrease after 60 min. Since the most 
significant increase was observed at 60 min, this was the time point at which the rest of the 
experiments were conducted.  
2.4.4 Proteasome inhibition increases HIF-1α stabilization more than hydroxylation 
inhibition 
To determine the contributions of both 20S and 26S proteasomal pathways to the 
degradation of HIF-1α in ischemic neurons, we carried out the experiments in the presence of 
proteasome inhibitors and prolyl hydroxylase domain enzyme (PHD) inhibitors.  As 
hydroxylation is a required step for HIF-1α to be degraded through the 26S degradation pathway 
but not the 20S pathway, PHD and proteasomal inhibitions would differentiate the individual 
contribution of the two pathways to HIF-1α degradation. MG-132 (10, 40 and 80 μM) was used 
to inhibit proteasome activities. DMOG at 0.5, 1 and 2 mM was used to inhibit prolyl 
hydroxylase.  These concentrations were selected based on previous reports. As Fig. 2.3 shows, 
OGD for 60 min increased HIF-1α level in primary cultured cortical neurons.  Pretreatment with 
MG-132 at 10 μM further elevated HIF-1α level (149% increase, compared to OGD only).    
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Table 2.1.  Effect of oxygen-glucose deprivation (OGD) on 26S and 20S proteasomal activity in 
primary cortical neurons. 
 
 
Primary cortical neurons were exposed to OGD for 30, 60 
or 90 min and then the 26S and 20S proteasomal activity 
was determined from the lysates. The increase in the 20S 
proteasome activity following both 30 and 60 min OGD 
exposure was found to be significant. *p < 0.05 vs. 0 min 
(n=3). 
 
  
  
  
OGD duration Proteasomal Activity (% of control) 
  
26S 20S 
0 min 100 100 
30 min 106.9 ± 5.51 104.8 ± 2.47* 
60 min 107.1 ± 3.86 114.4 ± 4.10* 
90 min 105.2 ± 2.75 100.5 ± 5.52 
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MG-132 at 40 and 80 μM induced a 172% and 174% increase of HIF-1α over OGD only, 
respectively. A smaller increase in HIF-1α level in the presence of higher levels of MG-132 
indicated that at 10 μM, MG -132 was able to effectively inhibit proteasomal activity in primary 
cultured neurons under OGD condition. Proteasomal inhibition has been linked to cell death, 
apoptosis and neurotoxicity with prolonged exposure (Williams et al., 2003; Williams et al., 
2004; Williams et al., 2005), therefore we chose to use the inhibitor at the lowest effective 
dosage and shortest incubation time in these experiments. Since there was no significant 
difference between MG-132 pre-treatment at 40 and 80 μM, the lower dose was used for 
evaluating the HIF-1α protein levels. DMOG was also able to further increase HIF-1α level, 
indicating that even under low oxygen conditions the 26S proteasomal pathway was involved in 
degrading HIF-1α protein.  We observed a 57% increase in HIF-1α protein levels in cells 
pretreated with 0.5 mM DMOG.  At 1 and 2 mM, DMOG caused an 83% and 93% increase, 
respectively, in the protein level. A higher concentration of DMOG did not cause a further 
increase in HIF-1α stabilization (Supplementary Fig.2.1C), indicating that inhibition of 
hydroxylation by DMOG at 2 mM is close to its maximal effect. Taken together, these data 
suggested that inhibiting the proteasome with MG-132 stabilized HIF-1α levels more than 
DMOG did under an OGD condition. 
Next we treated the neurons with a combination of both a proteasome inhibitor (40 μM MG-
132 or 8 μM epoxomicin) and a prolyl hydroxylase inhibitor (DMOG 2 mM). Neuronal viability 
was significantly increased with the combination treatment compared to the control normoxia 
conditions, OGD, and the individual drug treatments (Fig. 2.3B). Western blot analysis also 
showed that the combined drug treatments lead to a greater stabilization of HIF-1α (Fig. 2.3C).  
Immunoblotting for hydroxylated HIF-1α (HIF-OH) confirmed that DMOG was reducing  
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Figure 2.3A. HIF-1α protein stabilization with the treatment of proteasome and prolyl 
hydroxylase inhibitors. (A) Immunoblotting showing HIF-1α protein levels in neurons and the 
quantitative results for Western blot data. Equalization of protein loading was determined using 
β-actin as the housekeeping protein. *p<0.05 versus normoxia (N), #p<0.05 versus 
oxygen/glucose deprivation (OGD) (n= 3).  
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Figure 2.3B. Neuronal viability with the treatment of proteasome and prolyl hydroxylase 
inhibitors. Neurons were pre-treated with 40 μM MG-132, 2 mM Dimethyglycine (DMOG) or 8 
μM of Epoxomicin (Epox) and then exposed to oxygen and glucose deprivation (OGD). Cell 
viability was assessed using the MTT assay. *p <0.05 OGD, ^p <0.05 versus DMOG. (n = 3).  
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Figure 2.3C Immunoblotting showing HIF-1α and hydroxyl-HIF-1α (HIF-OH ) protein levels in 
neurons with the treatment of proteasome and prolyl hydroxylase inhibitors. Equalization of 
protein loading was determined using β-actin as the housekeeping protein. Quantitative results 
for Western blot data. *p<0.05 versus N, #p<0.05 versus OGD (n= 3)  
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Supplementary Figure 2.1.  HIF-1α protein stabilization following OGD with the treatment of 
MG-132 and DMOG. (A) Immunoblotting showing HIF-1α protein levels in neurons treated with 
either MG-132 (10, 40, 80, 100 μM) or DMOG (0.5, 1, 2, 3 mM). Equalization of protein loading 
was determined using β-actin as the housekeeping protein. (B) Curve demonstrating the HIF-1α 
protein levels with the pre-treatment of MG-132. (C) Curve demonstrating the HIF-1α protein 
levels with the pre-treatment of DMOG (n= 3) 
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hydroxylation of HIF-1α by inhibiting PHDs. The level of HIF-OH was highest under normoxia. 
It was decreased under OGD exposure and slightly increased with the inhibition of the 
proteasome. The combined drug treatment resulted in HIF-OH levels that were more than that of 
the DMOG treatment only but still lower than that with the proteasome inhibitors alone. 
 
2.4.5 Proteasomal inhibition is more effective than hydroxylase inhibition in reducing brain 
infarct size in an in vivo stroke model 
We then evaluated effects of proteasomal inhibition and hydroxylase inhibition on brain 
damage in an in vivo mouse stroke model.  Mice were subjected to MCAO followed by a 24 hr 
period of reperfusion. Four animal groups were examined: (1) Control, (2) Epoxomicin, (3) 
DMOG, and (4) Epoxomicin + DMOG. Epoxomicin was chosen as the proteasome inhibitor for 
the in vivo studies as it is able to cross the blood-brain barrier unlike MG-132 (Stefanis & Keller, 
2007) It is also more selective and potent than MG-132. Epoxomicin was administered at 1.1 
mg/kg/0.1cc as shown by Meng et al. (Meng et al., 1999a) to inhibit the proteasome. DMOG was 
administered at 50 mg/kg/0.1cc as shown by Ogle et al. (Ogle et al., 2012) to inhibit the PHD.  
Brain damage was assessed by calculating infarct and edema volume using TTC staining. The 
results revealed that epoxomicin was more effective at reducing infarct size compared to DMOG 
(Fig. 2.4B). We also assessed the infarct size following MCAO with the pretreatment with higher 
concentrations of DMOG to insure that a sufficient amount of DMOG was given to the mice to 
inhibit the PHD (Supplementary Fig. S2.2).  Epoxomicin was more effective than the increased 
concentrations of DMOG. Brain edema volume was also measured from the coronal sections. As 
shown in Fig. 2.4C, all 3 drug-treated animal groups had a significant decrease in edema volume 
following MCAO compared to the control mice. However, there was no significant difference  
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Figure 2.4. Effect of DMOG and epoxomicin on HIF-1a expression and brain damage induced by 
cerebral ischemia. Brain damage as determined by TCC staining after mice were subjected to 90 
min ischemia followed by 24 hr reperfusion. (A) Representative TTC staining of brain coronal 
sections taken from the 3 mm position of the frontal pole. (B) Quantification of infarct volume 
determined by TTC stained sections (n=5). Data presented as means ± SD *p < 0.05, vs. control 
untreated mice. #p < 0.05, vs. mice treated with Epoxomicin. (C) Quantification of brain edema 
volume estimated from TTC stained sections (n=5). Data presented as means ± SD *p < 0.05, vs. 
control untreated mice. (D) Immunoblotting showing the levels of HIF-1α from the ipsilateral and 
contralateral brain hemispheres of untreated mice and mice treated with dimethyloxalylglycine 
(DMOG), Epoxomicin (Epox) or a combination of both. (n=3) 
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Supplementary Figure 2.2. Brain damage as determined by TCC staining after mice were 
pretreated with DMOG and then subjected to 90 min ischemia followed by 24 hr reperfusion. 
(A) Representative TTC staining of brain coronal sections taken from the 3 mm position of the 
frontal pole. Mice were either pre-treated with a single dose of 50 mg/mL (24 hrs pre-MCAO), a 
triple dose of 50 mg/mL (16, 8 and 4 hrs pre-MCAO), a single dose of 100 mg/mL (24 hrs pre-
MCAO) or a single dose of 200 mg/mL (24 hrs pre-MCAO) (B) Quantification of infarct 
volume determined by TTC stained sections (n=5). Data presented as means ± SD *p < 0.05, vs. 
mice treated with a single dose of 50 mg/mL 
 
61 
 
between the groups. Furthermore, immunoblotting showed that HIF-1α protein levels were 
increased in the ipsilateral hemisphere and that it is significantly stabilized with the combined 
administration of Epoxomicin and DMOG.  
 
2.5 DISCUSSION 
The induction of HIF-1 is very important following cerebral ischemia. Dimerization of 
HIF-1α to HIF-1β leads to the expression of various genes that can promote cellular adaptation to 
conditions of low oxygen. Its targets include genes that code for molecules that participate in 
vasomotor control, angiogenesis, erythropoiesis, cell proliferation, and energy metabolism 
(Semenza, 2003a; b; Sharp & Bernaudin, 2004).  Each of these functions potentially contributes 
to the survival of neuronal cells. Neuron-specific HIF-1 deficient mice showed increased brain 
damage following MCAO (Baranova et al., 2007). The neuroprotective effects of iron chelators 
were also attributed to the activation of HIF-1 in vivo (Prass et al., 2002; Hamrick et al., 2005; 
Freret et al., 2006). HIF-1 can also promote adenosine production which has been shown to be 
neuroprotective (Heurteaux et al., 1995; Wardas, 2002; Lin et al., 2008). We investigated the 
mechanisms of HIF-1α degradation in neurons exposed to low oxygen conditions. The results for 
the first time demonstrated that both 20S and 26S proteasomal pathways were involved in HIF-
1α degradation in ischemic neurons. The results provide important information for not only 
understanding the pathophysiology of cerebral ischemia but also designing potential strategies 
for stroke treatment. 
Under normoxic conditions, HIF-1α is rapidly degraded via the ubiquitin-dependent 
proteasomal (26S) degradation pathway after hydroxylation and ubiquitination.  Under hypoxic 
conditions, it is generally regarded that HIF-1α is accumulated due to hydroxylation inhibition 
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(Wang et al., 1995b; Jiang et al., 1996; Wood et al., 1996; Salceda & Caro, 1997; Huang et al., 
1998a; Kallio et al., 1999; Huang & Bunn, 2003).  However, recent research suggests that HIF-
1α can also be degraded under hypoxia. Apart from the PHD hydroxylation pathway, there are 
other pVHL-dependent pathways that can degrade HIF-1α (Koh et al., 2008). During hypoxia 
HIF-1α levels can be regulated by the small ubiquitin- like modifier (SUMO)-1. SUMOylation 
can induce pVHL binding to HIF-1α thus promoting its ubiquitination and degradation by the 
26S proteasome (Cheng et al., 2007). There are also pVHL-independent pathways that lead to 
HIF-1 degradation (Koh et al., 2008). These signaling pathways involve the 90 kDa heat shock 
protein (HSP90) and the receptor of activated protein kinase (RACK1) (Liu et al., 2007) that 
lead to HIF-1α ubiquitination and degradation. Glycogen synthase kinase 3 (GSK3) (Flügel et 
al., 2007) as well as fork-head box (FOXO4) (Tang & Lasky, 2003) overexpression can also lead 
to pVHL-independent ubiquitination and HIF-1α degradation. All these mechanisms regardless 
of whether they are pVHL- dependent or – independent result in ubiquitination and therefore a 
likely degradation by the 26S proteasome. Demidenko et al. suggested that under hypoxia HIF-
1α may transcriptionally activate its own degradation, possibly mediated by acetylation 
(Demidenko et al., 2005). 
Recently, Kong et al. suggested that HIF-1α’s turnover under hypoxia was possibly regulated 
by the ubiquitin- independent proteasomal (20S) degradation pathway (Kong et al., 2007).  
Consistent with their observation, our current data clearly show that 20S proteasome can degrade 
HIF-1α in ischemic neurons. For HIF-1α to be a target of the 20S proteasome it would have to be 
oxidized as the 20S preferably degrade oxidized protein.  HIF-1α was found to be an oxidizable 
protein soon after it was discovered (Wang et al., 1995c; Huang et al., 1996) due to its residues 
with redox properties such as cysteine and methionine.  Oxidative modification of cellular 
63 
 
proteins was reported to occur within 10 min and peak at 1 or 2 hrs after the ischemic insults 
(Oliver et al., 1990; Hall et al., 1995).  Yet, it is not known which residue of HIF-1α is oxidized 
by ischemia.  Moreover, our data suggest that the 26S proteasomal pathway also contribute to the 
degradation of HIF-1α in ischemia, at least in our experimental setting.  As shown in Figure 2.3, 
PHD inhibition did prevent HIF-1α degradation. Our observation that proteasomal inhibition 
increased HIF-1α levels more than a PHD inhibitor under a low O2 condition  is in accordance 
with a previous report (Demidenko et al., 2005).  These results indicate that HIF-1α is, at least 
partly, degraded via a hydroxylation- independent proteasome pathway, and suggest that besides 
26S, the 20S proteasome is involved in the degradation of HIF-1α under hypoxia 
Currently PHD enzymes are being targeted for drug discovery in the treatment of stroke. PHD 
enzymes regulate the HIF-1α degradation pathway by acting as oxygen sensors (Epstein et al., 
2001). Therefore, the inhibition of PHD enzymes leads to the activation of HIF and its 
downstream genes. PHD inhibitors have been shown to be protective when administered prior to 
or upon reperfusion in brain ischemia models (Gu et al.; Gidday et al., 1994; Prass et al., 2002; 
Siddiq et al., 2005; Liu et al., 2009). However, inhibiting PHD may only provide a partial effect 
because HIF-1α can be degraded by other pathways such as the 20S proteasomes as shown here 
(Figures 2.3A). Our results reveal a novel mechanism of HIF-1α degradation mediated by ROS 
in the ischemic brain. We demonstrate that both the 26S and 20S proteasomal pathways are 
involved in HIF-1α degradation. Thus, PHD inhibitors are not as effective as the proteasome 
inhibitors because the PHD inhibitors will block hydroxylation of HIF-1α and the 26S pathway 
activity, but not the 20S pathway. Several studies have shown that the proteasome inhibitor 
MLN519 is neuroprotective in stroke injuries (Berti et al., 2003; Williams et al., 2003; Williams 
et al., 2004; Williams et al., 2005; Williams et al., 2006).  The application of proteasome 
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inhibitors in this study was mainly to investigate the mechanism of ROS mediated HIF-1α 
degradation in neurons during ischemia. An additional increase in HIF-1α levels when both the 
proteasome and prolyl hydroxylase are inhibited indicates a role of the 20S in HIF-1α 
degradation (Figure 2.3C). We also found that the combined treatment and the stabilization of 
HIF-1α was protective in both the in vitro primary neuron ischemia model and in the in vivo 
mouse stroke model in terms of maintaining cell viability (Figure 2.3B) and in the reduction of 
infarct size (Figure 2.4). 
The proteasome is a protein by itself, so it can be damaged by oxidative stress. The effect 
of oxidants on the function of the proteasome is still not very well understood. Its seems as 
though proteasome regulation is very complex and cells often give contradicting responses 
depending on the type and severity of the insult. Overall, studies report that the reactive oxygen 
species can alter the activities of the 26S and 20S proteasome. Although both the 26S and 20S 
can degrade oxidized proteins, many studies have determined that the contribution of the 20S is 
significantly higher (Davies, 2001; Breusing & Grune, 2008; Jung & Grune, 2008). This has 
been attributed to the fact that the 20S is more resistant to oxidative insults The 26S proteasome 
was in general more sensitive than the 20S proteasome to oxidants such as H2O2, hypochlorite, 
and peroxynitrite (Reinheckel et al., 1998a). The activity of the 20S proteasome after moderate 
oxidative stress did not change significantly (Grune et al., 2004). The 20S proteasome activity 
remained unchanged after H2O2 exposure of up to 2 mM, while the 26S proteasome was 
completely inhibited under these conditions (Reinheckel et al., 1998b). There is evidence that 
suggests that the chymotrypsin- like activity of the 20S proteasome is increased in response to 
ROS (Ullrich et al., 1999). Other studies have shown that 26S activity was also initially 
stimulated following oxidative stress and lead to cell protection. However, the mechanism of 
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how that occurred was unknown (Ding et al., 2003; Grune et al., 2004). Furthermore, the 
inhibition of the deubiquitinating enzyme, Usp14 (Lee et al., 2010) and the overexpression of the 
proteasome assembly protein, UMP1(Chen et al., 2006) both resulted in increased proteasomal 
function and increased cell viability in response to oxidative stress. 
In summary, HIF-1 plays an important role in the fate of ischemic neurons. 
Understanding the mechanism of HIF-1 induction is very important in determining its role in 
cerebral ischemia and providing potential approaches to regulate its expression. Our study 
reveals a novel mechanism of redox regulated HIF-1α stabilization during cerebral ischemia 
(Figure 2.5). We show that ROS can alter proteasomal activities in SH-SY5Y cells and that HIF-
1α can be oxidized which results in a significant increase in its degradation by the 20S 
proteasome. ROS consist of several unique species, which have dramatically different 
reactivities and half-lives.  Actions of ROS on HIF-1α degradation may be through specific 
reactive oxygen species, rather than ROS in general.  Understanding the different ROS species  
involved will provide us with a better understanding of the mechanisms.  It will also help us 
design more effective intervention strategies, such as efficient antioxidants, to inhibit or remove 
the specific species.  We also provide evidence that the inhibition of proteasomal activity with 
MG-132 and Epoxomicin  restored the attenuated accumulation of HIF-1α that resulted from 
increased ROS and provided neuroprotection (Figure 2.6). Regulating HIF-1α induction and the 
genes induced by HIF-1 under ischemia are highly promising therapeutic targets for cerebral 
ischemia (Giaccia et al., 2003; Williams et al., 2004; Shi, 2009). Defining this mechanism for 
HIF-1α degradation will make it possible to design more efficient agents for inhibiting HIF-1α 
degradation and promoting its neuroprotective properties. 
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Figure 2.5 Schematic diagram of HIF-1α degradation mechanisms under conditions of low 
oxygen and high oxidative stress.  
HIF-1α, hypoxia inducible factor-1α; ROS, reactive oxygen species; PHD, prolyl hydroxylase 
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Figure 2.6 Schematic diagram of proposed mechanisms of HIF-1α stailization. An oxidizing 
environment promotes HIF-1α degrdation through the activation of proteasomal pathways. 
Inhibiting the proteasome with MG-132 or Epoxomicin will lead to the accumulation of HIF-1α 
protein accumulation.  
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3.1 ABSTRACT 
Stroke is a major neurological disorder characterized by an increase in the Glu 
(glutamate) concentration resulting in excitotoxicity and eventually cellular damage and death in 
the brain. HIF-1 (hypoxia-inducible factor-1), a transcription factor, plays an important 
protective role in promoting cellular adaptation to hypoxic conditions. It is known that HIF-1α, 
the regulatable subunit of HIF-1, is expressed by astrocytes under severe ischemia. However, the 
effect of HIF-1 on astrocytes following Glu toxicity during ischemia has not been well studied. 
We investigated the role of HIF-1 in protecting ischaemic astrocytes against Glu toxicity. 
Immunostaining with GFAP (glial fibrillary acidic protein) confirmed the morphological 
modification of astrocytes in the presence of 1 mM Glu under normoxia. Interestingly, when the 
astrocytes were exposed to severe hypoxia (0.1% O2), the altered cell morphology was 
ameliorated with up-regulation of HIF-1α. To ascertain HIF-1's protective role, effects of two 
HIF-1α inhibitors, YC-1 [3-(50-hydroxymethyl-20-furyl)-1-benzylindazole] and 2Me2 (2-
methoxyoestradiol), were tested. Both the inhibitors decreased the recovery in astrocyte 
morphology and increased cell death. Given that ischemia increases ROS (reactive oxygen 
species), we examined the role of GSH (reduced glutathione) in the mechanism for this 
protection. GSH was increased under hypoxia, and this correlated with an increase in HIF-1α 
stabilization in the astrocytes. Furthermore, inhibition of GSH with BSO (l-butathione 
sulfoximine) decreased HIF-1α expression, suggesting its role in the stabilization of HIF-1α. 
Overall, our results indicate that the expression of HIF-1α under hypoxia has a protective effect 
on astrocytes in maintaining cell morphology and viability in response to Glu toxicity. 
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3.2 INTRODUCTION 
Brain ischemia induces a cascade of events that involve a loss of glucose and oxygen, 
membrane depolarization, and Glu (glutamate) release, leading to excitotoxicity. This release of 
the neurotransmitter Glu and subsequent calcium influx is considered to be the most significant 
event in the pathogenesis of ischaemic brain damage. Astrocytes play an important role in 
maintaining extracellular Glu that is released from neurons below toxic levels. They do so by 
clearing up Glu from the synaptic region through excitatory amino acid transporters and 
converting the Glu into glutamine by glutamine synthetase. Glutamine is then shuttled back to 
neurons and is re-used for Glu synthesis (Lehmann et al., 2009). Astrocytes are also involved in 
the metabolic support to neurons and provide them with nutrients such as lactate to supplement 
energy requirements. In addition, astrocytes appear to be the main source of EPO 
(erythropoietin) and GSH (reduced glutathione) in the CNS (central nervous system), having a 
GSH concentration twice as high that in neurons (Bolanos et al., 1995). There is significant 
evidence of astrocytes providing GSH and EPO to neighbouring neurons against various stresses 
(Gabryel and Malecki, 2006). Previous studies have shown that, in ischaemic infarcts, neurons 
do not survive if neighbouring astrocytes are not viable (Takano et al., 2009). Therefore it is 
important to examine how ischemia affects the function and viability of astrocytes. 
Under ischaemic conditions, HIF-1 (hypoxia- inducible factor-1) is expressed to promote 
cell survival. HIF-1 is a heterodimeric protein formed by a continuously expressed subunit HIF-
1β and an oxygen-regulated subunit HIF-1α that is stabilized under low oxygen levels. 
Activation of HIF-1 leads to the transcription of various genes that contribute to the cellular 
adaptation to these conditions. Some of the genes that play an important role in the protective 
effect of HIF-1 are those that are involved in angiogenesis such as VEGF (vascular endothelial 
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growth factor), erythropoiesis such as EPO and genes involved in glucose metabolism such as 
glucose transporters (Siddiq et al., 2007). It has been shown that HIF-1 induces high levels of 
EPO expression in astrocytes (Masuda et al., 1994), making them the main source of EPO in the 
CNS. This demonstrates that HIF-1 plays an important role not only in neurons but also in 
astrocytes. In addition, Glu release during cerebral ischemia causes the formation of ROS 
(reactive oxygen species) by the disruption of the mitochondrial electron transport chain and the 
activation of NAPDH oxidases (Brennan et al., 2009). Activation of HIF-1 has been shown to 
protect astrocytes against oxidative damage (Chu et al., 2010). 
Since astrocytes play an important role in maintaining brain homoeostasis and providing 
neuroprotection, their response to Glu toxicity and ischaemic insult requires further 
understanding. The main objective of this study was to investigate the effects of Glu on the 
viability and morphology of astrocytes exposed to hypoxia and the role that HIF-1 plays under 
these conditions. Our results demonstrate that HIF-1 has a protective effect on primary rat 
cortical astrocytes in terms of increasing cell viability and maintaining cell morphology in 
response to Glu toxicity and severe oxygen deprivation. Furthermore, we show that GSH may 
contribute to this protection by providing optimal conditions for HIF-1 stabilization. 
3.3 MATERIALS AND METHODS 
3.3.1 Primary culture of astrocytes 
All experiments were conducted with the approval of the University of Kansas 
Institutional Animal Care and Use Committee. Cortical tissue were dissected from the Sprague–
Dawley rat (Charles River Laboratories) brains at postnatal day 0 (P0) to P4. The tissues were 
washed with HBSS (Hanks balanced salt solution) and trypsinized for 50 min at 37°C. The 
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tissues were then dissociated using a fire polished glass pipette in a dissociation medium (HBSS, 
0.1% BSA and 8 mM MgCl2), and centrifuged at 4000 g for 4 min at room temperature (22°C). 
The cells were transferred into and grown in 25 cm2 flasks with DMEM (Dulbecco's modified 
Eagle's medium) and 10% FBS (fetal bovine serum). After 3–4 weeks the flasks were shaken to 
purify the astrocytes by dislodging other cell layers. Following purification, astrocytes were 
plated on coverslips with DMEM and 10% FBS and used for experiments after 10–12 days. 
3.3.2 In vitro hypoxia model 
Hypoxia was induced by incubating the astrocytes in 0.1% O2/5% CO2 (balanced with 
N2) in a hypoxia chamber (COY Laboratories) for 3 h. To mimic the high levels of Glu release 
during ischemia, astrocytes were treated with 0, 0.001, 0.01, 0.1 and 1 mM of Glu in serum-free 
medium (DMEM) at 37°C for 3 h. Control experiments were conducted at 21% O2/5% CO2. 
3.3.3 Drug treatments 
YC-1 [3-(50-hydroxymethyl-20-furyl)-1-benzylindazole] and 2Me2 (2-
methoxyoestradiol; Cayman Chemical Company) were used for HIF-1α inhibition studies. Prior 
to hypoxia exposure, the astrocytes were incubated with 0.1 mM of the inhibitors for 1 h. 
Preliminary experiments showed that these conditions were sufficient for HIF-1α inhibition 
during severe hypoxia, as shown in Figure 3.3. For GSH depletion, astrocytes were pre-
incubated with 5 mM BSO (l-butathione sulfoximine; Sigma–Aldrich) for 12 h as described 
by Noda et al. (2001). The BSO was present for an additional 3 h during the hypoxia treatment to 
inhibit the re-synthesis of GSH. 
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3.3.4 Immunocytochemistry 
Following treatments, astrocytes were washed with PBS and fixed with 4% PFA 
(paraformaldehyde) for 20 min at room temperature. The cells were then permeabilized using 
0.3% Triton X-100 for 15 min at room temperature and incubated in a blocking solution (0.05% 
Triton X-100 and 0.25% BSA dissolved in PBS) for 30 min at room temperature. Astrocytes 
were incubated with primary antibodies of GFAP (glial fibrillary acidic protein) (1–500, 
MAB3402, Millipore) and HIF-1α (1–100, sc-8711, Santa Cruz Biotechnology) overnight at 
4°C. Cells were washed and incubated with the appropriate secondary antibodies [GFAP: donkey 
anti-mouse TRITC (tetramethylrhodamine β-isothiocyanate) (1–50; Jackson ImmunoResearch) 
and HIF-1α: goat anti-rabbit conjugated to Alexa Fluor® 488 (1–100; Molecular Probes)]. 
Coverslips were washed and mounted by using Vectashield mounting medium with DAPI (4′,6-
diamidino-2-phenylindole; Vector Laboratories). Images were acquired on a Leica DMI4000 
microscope with a ×40 objective and a Leica DFC340 FX digital camera. 
3.3.5 GSH measurement 
The GSH level was measured by using the MCB (monochlorobimane) method 
(Chatterjee et al., 1999). Following the treatments, astrocytes were incubated with 0.1 mM of 
MCB for 30 min at 37°C. Fluorescence images were then taken immediately, directly from the 
culture dish. For co-localization studies, the astrocytes were fixed after the MCB treatment and 
double-stained for GFAP and HIF-1α using the immunocytochemistry procedure described 
above. The intensity of the fluorescent GSH conjugate (GSH–MCB) of single cells was 
measured from the images using ImageJ software. Readings of whole-cell intensity were taken 
from 15 cells from three different culture preparations. 
82 
 
3.3.6 Cytotoxicity assessment 
Cell death was assessed by measuring the activity of LDH (lactate dehydrogenase) in the 
culture medium using an LDH cytotoxicity assay kit (Cayman) as described by Bonfoco et al. 
(1995). The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay kit 
(Invitrogen) was also used to assess cell survival and to quantify the Glu-mediated cytotoxicity 
as described by Mosmann (1983). 
3.3.7 Immunoblot analysis 
Astrocytes were lysed in 200 μl of RIPA buffer (Thermo Scientific) and the protease 
inhibitor cocktail kit (Thermo Scientific) and scraped with the aid of a cell lifter (Biologix 
Research Company). The lysates were centrifuged at 15300 g for 10 min at 4°C, and the protein 
concentration of the supernatants was determined using a protein assay kit (Bio-Rad). Proteins 
were separated by SDS/PAGE and the separated proteins were transferred to a nitrocellulose 
membrane (Bio-Rad). After being blocked with 5% (w/v) non-fat dried skimmed milk powder in 
TBST (Tris-buffered saline with Tween), the membrane was incubated with the primary 
antibody (HIF-1α: 1–1000; BD Transduction Laboratories) overnight at 4°C and the secondary 
antibody (1–3000; goat anti-mouse; Santa Cruz Biotechnology) for 1 h at room temperature. 
Immunoblots were quantified using ImageJ software and HIF-1α levels were normalized to β-
actin. 
3.3.8 Texture analysis 
Changes in astrocyte texture were determined using CellProfiler cell image analysis 
software as described previously by Haralick et al. (1973) and Carpenter et al. (2006). 
Quantification of texture was done from fluorescence images from three different culture 
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preparations. Five microscopic fields were obtained from each culture dish and readings from six 
to eight cells were taken for further analysis. 
3.3.9 Statistical analysis 
Data are presented as means±S.D. from a minimum of three independent experiments. 
One-way ANOVA and the Student's t test were used for overall significance. Differences 
of P<0.05 were considered statistically significant. Image-Pro Plus 5.1 (Media Cybernetics), 
ImageJ and Excel were used for data analyses. 
3.4 RESULTS 
3.4.1 Severe hypoxia-protected astrocytes from Glu toxicity 
Excessive Glu accumulation is a major cause of neuronal death in the brain during 
ischemia. Astrocytes are very important for the clearance of excessive Glu from the extracellular 
space; however, high concentrations of Glu also affect astrocytes and can lead to their death 
under normal conditions. Here, we studied the morphological changes in primary rat cortical 
astrocytes exposed to Glu at various concentrations (0, 0.001, 0.01, 0.1 and 1 mM) for 3 h. The 
morphology was assessed based on GFAP expression. Lower concentrations (0.001 and 0.01 
mM) of Glu had no effect on the morphology. Increased concentrations (0.1 and 1 mM) caused 
changes in the structure of the astrocytes (Figure 3.1A). Under control conditions, astrocytes 
appeared fibrous. However, high Glu resulted in a disrupted or diffuse- like structure. To quantify 
the GFAP-based structural/morphological changes, we conducted texture analysis by using 
CellProfiler which measures the amount of local variation present (Carpenter et al., 2006). A 
higher value with more contrast suggests a more complex structure. The results demonstrate that 
Glu altered the astrocyte morphology under normoxia, compared with the control (no Glu). 
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Interestingly, when astrocytes were exposed to severe hypoxia (0.1% O2) in the presence of 1 
mM Glu, the astrocyte morphology was improved when compared with 1 mM Glu under 
normoxia. These data are evidence that hypoxia protects astrocytes against Glu toxicity. As the 
low concentrations of Glu had no effects on astrocyte morphology, the following studies were 
carried out with 0.1 and 1 mM Glu. 
To further examine the protective effect of hypoxia on astrocyte against Glu, we 
measured cell death with the LDH assay as shown in Figure 3.1(C). Under normoxia, there was a 
Glu-concentration-dependent decrease trend in astrocyte viability. Under severe hypoxia there 
was a sign of recovery. When cell viability was determined with the MTT assay, we observed a 
significant decrease in cell viability when astrocytes were exposed to 1 mM Glu under normoxia 
and a significant recovery in astrocyte survival under hypoxia. The difference in the cell viability 
may be due to the sensitivity of the two cytotoxicity assays. The LDH assay requires a more 
severe insult that causes damage to the cell membrane. The MTT assay on the other hand works 
by measuring the metabolic activity of the mitochondria. Nevertheless, results from both assays 
indicate that hypoxia reduces astrocyte damage caused by Glu. 
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Figure 3.1. Hypoxia ameliorated astrocyte damage induced by glutamate (Glu). (A) 
Immunostaining characterization of cultured rat cortical astrocytes. Representative images 
depicting GFAP (red) in astrocytes treated with 0, 0.001, 0.1, 0.1 and 1 mM Glu under normoxia 
(21% O2) and 1mM exposed to severe hypoxia (0.1% O2) for 3hrs. (B) Morphologic profiling of 
astrocytes stained for GFAP and DAPI (for nucleus staining). Individual cells were identified 
using CellProfiler software and divided with clear boundaries (1).  Representation (3) of 
quantification of morphology using one of the 13 features computed from each cell to measure 
and compare texture (2). *p < 0.05 vs. 0 mM Glu under normoxia. (C) Astrocyte viability 
assessed using the LDH and MTT assay. *p < 0.05 vs. 0 mM Glu under normoxia, #p < 0.05 vs. 
1 mM Glu under normoxia. (n=3) 
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3.4.2 HIF-1α is highly expressed in astrocytes under severe hypoxia 
Next, we aimed to address the mechanism by which the astrocytes recovered from the 
Glu toxicity during severe hypoxia. It is known that HIF-1α is stabilized under low oxygen levels 
and can contribute to cellular protection under these conditions. HIF-1α expression was first 
analysed by immunostaining. As expected, there was no HIF-1α expression under normoxia, 
while treatments with severe hypoxia increased HIF-1 expression in the nuclei of the astrocytes 
(Figure 3.2A). HIF-1α was also expressed in the nucleus of the astrocytes following severe 
hypoxia treatment in the presence of Glu. For further confirmation, Western-blot analysis 
demonstrated a significant increase in HIF-1α protein levels under severe hypoxia, both with and 
without Glu treatments (Figure 3.2B). However, with 1 mM Glu under severe hypoxia there was 
a slight decrease in the HIF-1α protein levels. This could be due to increased proteasomal 
degradation induced by an increase in ROS (see the Discussion for further explanation). 
3.4.3 HIF-1α inhibition attenuates the recovery of astrocytes from Glu toxicity under severe 
hypoxia 
To confirm whether the recovery of the cell morphology and cell viability under severe 
hypoxia was in fact due to the expression of HIF-1α, the effect of two HIF-1α inhibitors, YC-1 
and 2Me2, were examined on astrocyte damage. Although the mechanism of HIF-1α inhibition 
by YC-1 and 2Me2 is not fully understood, it appears as though YC-1 acts at a post-translational 
level and inhibits HIF-1α activation (Li et al., 2008), while 2Me2 inhibits HIF-1α at the level of 
translation (Mabjeesh et al., 2003). Astrocytes were pre-treated with a 0.1 mM concentration of 
the inhibitors for 1 h and then subjected to severe hypoxia with the addition of 1 mM Glu for an 
additional 3 h. Astrocytes treated with YC-1 or 2Me2 showed much less HIF-1α expression in  
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Figure 3.2. HIF-1α expression was increased in astrocytes exposed to severe hypoxia and 
glutamate (Glu). (A) Representative immunofluorescent images showing GFAP (red) and HIF-
1α (green) labeling in astrocytes treated with 0, 0.1, and 1 mM Glu under normoxia (N) or severe 
hypoxia (SH) for 3 hrs. (B) Protein stabilization of HIF-1α determined by Western blot analysis. 
Equalization of protein loading was determined using β-actin as the housekeeping protein.  *p < 
0.05 vs. 0 mM Glu under N. (n=3) 
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the nuclei of astrocytes under severe hypoxia in the presence of 0 and 1 mM Glu (Figure 3.3A). 
The immunostaining also reveals that the addition of either YC-1 or 2Me2 resulted in an 
attenuation of the recovery of the cell morphology when compared with the controls. Western 
blotting confirmed that the inhibitors did decrease the HIF-1α protein level (Figure 3.3B). 
Table 3.1 shows the effects of the two HIF-1 inhibitors on cell morphology quantified by 
the texture analysis and cell viability assays. Both YC-1 and 2Me2 treatments resulted in a 
significant change in cell morphology and significant increase in cell death. Astrocytes treated 
with the HIF-1α inhibitors under normoxia showed no significant effect (Table 1). The increase 
in cell death was consistent with no recovery in texture with either YC-1 or 2Me2 treatment 
under severe hypoxia. This suggests that the recovery in astrocyte morphology is caused by the 
stabilization of HIF-1α under low oxygen levels. 
3.4.4 GSH stabilizes HIF-1α expression 
GSH is the most abundant small molecule anti-oxidant that suppresses free radical levels 
and protects cells against various stress conditions. Previous data from our laboratory has shown 
that GSH increases HIF-1α expression during oxygen deprivation (Guo et al., 2008). To 
determine whether GSH plays a role in the HIF-1α stability and protective effect in astrocytes, 
we compared GSH levels between the different treatments. The cellular GSH level was measured 
using the MCB method. Fluorescence intensities of GSH-MCB were quantified to differentiate 
between the levels of GSH present in astrocytes treated with 0.1 and 1 mM Glu under normoxia 
versus severe hypoxia. The results showed no change in GSH levels in the presence of Glu lower 
than 0.1 mM under normoxia; however, 1 mM Glu caused a significant increase in GSH (Figures  
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Figure 3.3. YC-1 and 2Me2 attenuated the protection provided by hypoxia in astrocytes. 
(A) Representative immunofluorescent images demonstrating the effect of YC-1 and 2Me2 on 
HIF-1α (green) expression and astrocyte morphology (GFAP, red).  Astrocytes were pre-treated 
with 0.1 mM YC-1 and 2Me2 followed by 1 mM Glu with exposure to normoxia (N) or severe 
hypoxia (SH) 3 hrs.  (B) Protein stabilization of HIF-1α determined by Western blot analysis. 
Equalization of protein loading was determined using β-actin as the housekeeping protein.   *p < 
0.05 vs. 0 mM Glu under N, #p < 0.05 vs. 0 mM Glu under SH. (n=3) 
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Glu concentration Treatment Texture Analysis Cell Viability 
      
LDH Assay (%) MTT Assay (%) 
0 mM N 1.49 ± 0.12 100 100 
 
N + YC-1 1.19 ± 0.04  99.12 ± 3.09 98.22 ± 1.74 
 
N + 2Me2 1.13 ± 0.03  99.47 ± 2.52 97.95 ± 2.57 
 
SH 1.07 ± 0.24 97.35 ± 1.79 90.82 ± 2.93 
 
SH + YC-1 0.97 ± 0.31 66.15 ± 6.42
# 62.74 ± 2.20# 
 
SH + 2Me2 0.89 ± 0.28 66.34 ± 1.96
# 64.41 ± 3.09# 
1 mM N 0.52 ± 0.06* 94.09 ± 1.49 82.84 ± 1.77* 
 
N + YC-1 0.44 ± 1.08* 98.29 ± 1.51 80.42 ± 5.03* 
 
N + 2Me2 0.48 ± 1.11* 97.30 ± 3.24 81.03 ± 4.12* 
 
SH 0.89 ± 0.05** 95.17 ± 3.42 89.86 ± 4.02 
 
SH + YC-1 0.55 ± 0.11* 59.44 ± 3.59
# 55.91 ± 5.24# 
  SH + 2Me2 0.51 ± 0.05* 65.56 ± 5.14
# 58.62 ± 3.37# 
 
Results were presented as mean ±SD (n=3) 
   
N, normoxia; SH, severe hypoxia 
   * p < 0.05 vs. N 
 ** p < 0.05 vs. N 1mM 
 # p < 0.05 vs. SH 0 mM 
    
  
Table 3.1. Effect of HIF-1α inhibitors on astrocytes exposed to Glu and hypoxia 
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3.4A and 3.4B) Hypoxia increased the GSH levels in astrocytes. The presence of Glu further 
increased the GSH level in astrocytes exposed to hypoxia. 
To determine whether an increase in GSH levels contributed to the up-regulated HIF-1α 
expression, we fixed the cells after MCB treatment with or without severe hypoxia in the 
presence of Glu and then co-stained for GFAP and HIF-1α. The results showed a co-localization 
of increased GSH with HIF-1α expression in astrocytes treated with both 0.1 and 1 mM Glu 
(Figure 3.4C). This suggests that GSH might help stabilize HIF-1α expression in the astrocytes. 
To confirm the role of GSH in the HIF-1α up-regulation, astrocytes were pre-treated with 5 mM 
BSO, which decreases cellular GSH levels, for 12 h and then exposed to Glu and hypoxia. This 
resulted in a significant attenuation of HIF-1α stabilization (Figure 3.5). Furthermore, inhibition 
of GSH and consequently HIF-1α, decreased astrocyte survival and abolished the morphological 
recovery under hypoxia (Table 3.2). These results are consistent with the results of HIF-1α 
inhibition using YC-1 and 2Me2; indicating that HIF-1 provides protection against Glu in 
hypoxic astrocytes. 
3.5 DISCUSSION 
To date, there are no effective neuroprotectants for human stroke, and the development of 
neuroprotective strategies is considered extremely challenging. Although many agents have been 
tested for the treatment of ischaemic stroke, such as anti-oxidative, anti-apoptotic, anti-
excitotoxic and anti-inflammatory drugs, they have all proved unsuccessful. One of the reasons 
for this may be our incomplete understanding of the mechanisms that are responsible for cellular 
death. Furthermore, the study of cell death following cerebral ischemia has been primarily 
focused on neurons. In addition to neurons, ischemia also causes damage to astrocytes (Martin et 
al., 1997; Yu et al., 2001; Lukaszevicz et al., 2002; Giffard and Swanson, 2005), which are 
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 Figure 3.4. Astrocyte GSH levels were increased with Glu and severe hypoxia treatments. 
Astrocytes were treated with 0.1 mM or 1 mM Glu with exposure to normoxia (N) or severe 
hypoxia (SH) for 3 hrs.  Astrocytes were loaded with 0.1 mM MCB following treatments. (A) 
Representatives of GSH-MCB labeling in astrocytes exposed to various conditions. (B) 
Quantification of the cytosolic GSH intensity in astrocytes exposed to various conditions. *p < 
0.05 vs. 0 mM Glu under N, #p < 0.05, N vs. SH for each Glu concentration (C) Colocalization 
of GFAP (red), HIF-1α (green) and GSH (blue) in astrocytes treated with 0, 0.1 and 1 mM Glu 
under normoxia or severe hypoxia. (n=3) 
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Figure 3.5. GSH inhibition reduces HIF-1α expression. (A) Representative 
immunofluorescence images demonstrating the effect of buthionine sulfoximine (BS0) on HIF-
1α (green) expression and astrocyte morphology.  Astrocytes were pre-treated with 5 mM BSO 
followed by 1 mM Glu with exposure to severe hypoxia (SH) and compared to astrocytes treated 
with 0 and 1 mM Glu under severe hypoxia only. HIF-1α intensity was measured and normalized 
to the control. *p < 0.05 vs. 0 mM Glu under N, #p < 0.05 vs. 1 mM Glu under SH. (B) 
Immunoblotting showing HIF-1α protein levels. Equalization of protein loading was determined 
using β-actin as the housekeeping protein.  Quantitative results for Western blot data. *p < 0.05 
vs. 0 mM Glu under N. (n=3) 
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Glu concentration Treatment Texture analysis Cell viability 
    
  LDH assay (%) MTT assay (%) 
0 mM SH 1.10 ± 0.13 100 100 
 
SH + BSO 0.59 ± 0.18* 63.70± 3.29* 57.36 ± 4.69* 
1 mM SH 0.96 ± 0.13* 96.14 ± 1.17 97.06 ± 2.37 
  SH + BSO 0.54 ± 0.17*# 60.68 ± 2.79*# 54.35 ± 5.26*# 
 
Results were presented as mean ±SD (n=3) 
  
     N, normoxia; SH, severe hypoxia 
   * p < 0.05 vs. SH 
 # p < 0.05 vs. SH 1mM 
 
Table 3.2. Effect of L-butathione sulfoximine (BSO) on HIF-1α induced protection of astrocytes 
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critical in maintaining neuronal viability and functions under ischaemic conditions. Therefore 
targeting astrocytes can be an important strategy to enhance neuronal survival. 
 Recently, HIF-1 is being focused on as a potential target for stroke therapy as it appears 
to have many beneficial roles in the ischaemic brain (Baranova et al., 2007). Although HIF-1 has 
been shown to have a protective effect specifically in astrocytes in neurological diseases such as 
Alzheimer's disease (Schubert et al., 2009), few studies have been done to investigate the effect 
of HIF-1α expression on astrocytes during stroke. 
Given the increase in Glu in the ischaemic brain and the scavenging function of 
astrocytes on Glu, we examined the effects of Glu on the viability and morphology of astrocytes 
exposed to hypoxia. Compared with neurons, astrocytes are very resistant to hypoxia due to 
several factors. First, astrocytes have large glycogen stores (Phelps, 1972) that can be 
metabolized to glucose and lactate and supply energy during ischemia and glucose deprivation 
(Swanson and Choi, 1993). Secondly, astrocytes have a low energy demand, unlike neurons, 
which have a high density of ion channels and require more ATP to maintain ionic gradients. 
Thus ionic deregulation occurs slowly in astrocytes (Silver et al., 1997). Thirdly, astrocytes have 
a higher level of GSH, an important antioxidant, than neurons and provide GSH or substrates for 
GSH synthesis to neurons (Makar et al., 1994, Chen and Swanson 2003). In our experiments, 
astrocytes were exposed to severe hypoxia (0.1% O2) because a milder hypoxic exposure (1% 
O2) was not sufficient to cause any significant changes in HIF-1α expression (data not shown). 
As the results demonstrated, Glu caused a concentration-dependent change in astrocyte 
morphology, which resembled a more diffuse-like structure from a fibrous one, under normoxia. 
This was correlated with a decrease in cell viability determined by LDH and MTT assays. 
Interestingly, when the astrocytes were treated with the same Glu concentrations under severe 
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hypoxia there was a recovery in cell morphology and cell viability. Our observation is consistent 
with a previous study that demonstrated that pre-treatment with hypoxia reduced astrocyte 
damage by 45–55% (Chen et al., 2000). 
One of the remarkable observations in our study is that increased GSH is not sufficient to 
protect astrocytes from damage induced by Glu under normoxia. As shown in Figures 3.4(A) and 
4(B), Glu at 1 mM significantly elevated the GSH level in astrocyte under normoxia and induced 
significant cell damage detected by cellular texture and viability (Figure 3.1). In contrast, under 
hypoxic conditions the increase of GSH was accompanied by improved cellular texture and 
astrocyte viability (Figures 3.1 and 3.4). This protective effect provided in the hypoxic 
conditions is largely ascribed to the expression of HIF-1, since inhibiting HIF-1 abolished the 
protection (Figure 3.3 and Table 3.1). Furthermore, stabilizing HIF-1α expression under 
normoxia with cobalt chloride appeared to have an even more significant effect in the recovery 
of cell morphology (Supplementary Figure S3.1B) Taken together, these findings strongly 
support that the activation of HIF-1 is responsible for promoting the astrocytic survival and 
protection against Glu toxicity under hypoxia. 
Many factors may contribute to HIF-1-mediated protection in hypoxic astrocytes. First, 
HIF-1 up-regulates EPO (Semenza et al., 1997), which provides cellular protection under 
different stresses. Many studies have examined the effect of EPO on astrocytes, since they are 
the main source of EPO in the brain. For example, EPO has been shown to protect astrocytes 
from damage in response to oxidative stress (Liu et al., 2006) and other agents that induce 
apoptosis (Diaz et al., 2005). Secondly, HIF-1 leads to the induction of VEGF in astrocytes 
(Sinor et al., 1998). VEGF has been shown to play an important role in cellular protection in 
hypoxic preconditioning (Wick et al., 2002) by promoting angiogenesis (Jin et al., 2000). A  
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Supplementary Figure 3.1. Cobalt chloride (CoCl2) further reduced astrocyte damage 
induced by glutamate (Glu). (A) Immunostaining characterization of cultured rat cortical 
astrocytes. Representative images depicting GFAP (red) and HIF-1α (green) in astrocytes treated 
with 0.3 mM CoCl2 and 1 mM Glu under normoxia (N, 21% O2) for 3 hrs. (B) Quantification of 
morphology using one of the 13 features computed from each cell to measure and compare 
texture. Astrocytes were treated with 0 and 1 mM Glu under normoxia (N, 21% O2), 1 mM Glu 
exposed to severe hypoxia (SH, 0.1% O2) and 0.3 mM CoCl2 and 1 mM Glu under normoxia (N, 
21% O2) for 3 hrs. *p < 0.05 vs. 0 mM Glu under N, #p < 0.05 vs. 1 mM Glu under N, #p < 
0.005 vs. 1 mM Glu under N (n=3). 
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study by Mani et al. (2005) has revealed that exogenous VEGF induces astrocyte proliferation. In 
addition, HIF-1 may promote the production of adenosine that offers neuroprotective properties 
(Heurteaux et al., 1995; Wardas 2002; Lin et al., 2008). Adenosine binds to the presynaptic A1 
receptor and may lead to a decrease in Ca2+ influx. This further decreases the release of Glu and 
excitation of the NMDA (N-methyl-D-aspartate) receptors, thus preventing cellular damage 
caused by the subsequent increases in Ca2+ influx (Monopoli et al., 1998;Wardas 2002). A study 
by Batti et al. (2010) has shown that the stabilization of HIF-1α through prolyl hydroxylase 
inhibition protected against Glu-induced damage in the hippocampus of the rat ischaemic brain 
mainly through adenosine accumulation in response to hypoxia. A review article by Vangeison 
and Rempe (2009) clearly describes how hypoxia and HIF-1 can regulate various proteins, 
including connexin 43, CD73 and the ENT-1 (equilibrative nucleoside transporter 1), which 
ultimately leads to enhanced adenosine levels. Of these, both CD73 and ENT-1 have been shown 
to be regulated by HIF-1 in intestinal epithelia (Synnestvedt el al. 2002) and endothelial cells 
(Eltzschig et al., 2005) respectively. CD73 and ENT-1 are expressed in astrocytes (Vangeison 
and Rempe 2009); therefore it is possible that HIF-1 can regulate their activity and increase 
adenosine in astrocytes. In fact, it has been shown that adenosine has a direct protective effect on 
rat primary astrocytes by reducing death induced by glucose deprivation (Shin et al., 2002) and 
in reducing damage in human astroglioma D384 cells following oxygen deprivation through the 
preservation of ATP levels (Bjorklund et al., 2008). 
The results presented in this paper clearly demonstrate that GSH increases the HIF-1α 
level in astrocytes exposed to hypoxia. As shown in Figure 3.4, there was an increase in GSH 
following the 3 h Glu and severe hypoxia treatment. In addition, BSO, which inhibits GSH 
synthesis, decreased HIF-1α expression. Our results are consistent with previous studies that 
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have shown that altering redox status can effect HIF-1α expression in other types of cells. 
Inhibition of GSH synthesis by BSO reduced HIF-1α expression in lung epithelial cells (Haddad 
and Land, 2000) and in hepatic cells (Jin et al., 2011). Treatment with N-acetylcysteine, the GSH 
precursor, increased HIF-1α expression in lung epithelial cells (Haddad et al., 2000) and in 
hepatic cells (Sommani et al 2007; Jin et al., 2011). Our previous results have also demonstrated 
that HIF-1α stability favours a reducing environment in neurons (Guo et al., 2008). Recently, 
Tajima et al. (2009) showed that the induction of HIF under hypoxia is regulated by the redox 
state of GSH in HSC-2 (human oral squamous cells). They suggest that GSH can regulate the 
activation of HIF by directly binding to the thiol groups of regulatory cellular proteins. Since 
HIF-1α is sensitive to redox status and can be degraded by increased ROS (Liu et al., 2004; 
Wellman et al., 2004), it is reasonable to consider that the mechanism by which GSH increases 
HIF-1α is through the clearance of excessive ROS and by promoting a suitable reducing 
environment that prolongs its stabilization. Our immunoblot results showed that, under 
normoxia, there was an increase in HIF-1α levels when astrocytes were treated with 1 mM Glu. 
Even though this increase was not significant, it did correlate with increased GSH levels. It 
seems as though GSH is able to stabilize HIF-1α and reduce its degradation when it is normally 
expressed during hypoxia. However, during normoxia, the oxygen levels are sufficient to 
maintain prolyl hydroxylase activity and target HIF-1α for ubiquitination. 
Meanwhile, HIF-1 may increase the level of GSH in hypoxic astrocytes, as shown in our 
results. Others have also reported that HIF-1 is able to maintain GSH levels in brains of rats 
exposed to hypoxia (Shrivastava et al, 2008). In addition, previous studies have shown that HIF-
1 can protect astrocytes from ROS-induced injury (Chu et al., 2010) and that GSH depletion 
induces astrocytic death in response to ROS (Im et al., 2006). All these results indicate that 
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maintaining GSH levels and reducing ROS toxicity is part of HIF-1-mediated neuroprotection. 
Based on our results and others, we postulate the GSH–HIF-1 crosstalk in hypoxic astrocytes 
(Figure 3.6). Hypoxia induces accumulation of HIF-1, which subsequently switches on the 
expression of genes that promote cell survival such as glucose transporters and glycolytic 
enzymes, EPO, VEGF, HSPs (heat-shock proteins) (Baird et al., 2006), HO-1 (haem oxygenase 
1) (Shrivastava et al., 2008), etc. Some of the genes such as EPO and VEGF provide direct cell 
protection against hypoxic stress. Others, such as those of glucose metabolism, HSPs and HO-1, 
may increase the level of GSH, contributing to HIF-1 stabilization. 
In conclusion, there are still large gaps that exist in our understanding of how astrocytes 
are affected during stroke. Given that the release of the Glu is considered to be the leading cause 
of brain damage following stroke, we determined the effect of HIF-1α expression and 
stabilization on how astrocytes respond to Glu toxicity during stroke. Our study has shown that 
HIF-1α expression protects astrocytes from Glu-induced damage. We also provide evidence that 
GSH plays a role in HIF-1α stabilization and promotes its protective effect. Taking this fact into 
consideration will lead to a better understanding of the protective mechanisms of astrocytes and 
provide a more effective approach not only to stroke therapy but also other pathological 
conditions that cause, or are exacerbated by, excitotoxicity. 
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Figure 3.6. Schematic diagram of GSH-HIF-1 cross-talk in promoting cell survival during 
hypoxia. Hypoxia leads to HIF-1 stabilization which subsequently activates the expression of 
various pro-survival genes. These include erythropoietin (EPO), vascular endothelial growth factor 
(VEGF), heat shock proteins (HSPs), heme oxygenase 1(HO-1) and proteins that increase glucose 
metabolism such as glucose transporters and glycolytic enzymes. Genes such as those of glucose 
metabolism, HSPs, and HO-1 may increase the level of GSH causing it to exert its anti-oxidant 
effect and promote survival. In addition, the reducing environment created by GSH can in turn 
contribute to HIF-1 stabilization. 
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Chapter 4: Ischemic Tolerance in an in vivo model of Glutamate 
“Preconditioning” 
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4.1 INTRODUCTION 
Stroke results in a rapid cessation of blood flow that compromises energy metabolism in 
the affected brain tissue and leads to enhanced glutamate release (Benveniste et al., 1984). 
Glutamate is ubiquitously distributed in the brain and is present in concentrations that are higher 
than any other amino acid (Fonnum, 1984), making it the principal excitatory neurotransmitter in 
the nervous system. Early studies demonstrated that blocking ionotropic glutamate receptors 
significantly reduced ischemic damage (Sims & Muyderman, 2010). This was attributed to its 
involvement in the excitotoxic cascade in which the increased glutamate release causes an 
excessive accumulation of calcium (Ca2+) that triggers downstream pathways that cause cell 
death. Therefore, impeding excitotoxicity in experimental stroke models has been the most 
targeted mechanism in the development of neuroprotective treatments for stroke (O'Collins et al., 
2006; Minnerup et al., 2012). In stroke patients, the effect of over 20 anti-excitatory drugs was 
evaluated in over 270 preclinical studies, none of which demonstrated a beneficial effect 
(O'Collins et al., 2006). However, experimental studies on potential strategies to protect neurons 
have continued to increase over the last few years (Ginsberg, 2008; Minnerup et al., 2012).   
A current focus is on understanding the protective mechanisms that induce tolerance 
following ischemic preconditioning. Current knowledge suggests that preconditioning with a 
brief period of ischemia is an effective approach to decrease neuronal death after a more severe 
ischemic episode (Kirino, 2002). The same concept can be applied to excitotoxicity where 
preconditioning with a mild glutamate- induced stress can promote a tolerant state that reduces 
the injury caused by a subsequent, more severe glutamate exposure. Few studies have used 
glutamate preconditioning to evaluate the development of resistance to a subsequent ischemic 
insult. Lin et al. (2008) showed that neuronal death following in vitro ischemia was prevented by 
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glutamate preconditioning through the anti-apoptotic protein, Bcl-2 (Lin et al., 2008). Other 
studies were also primarily focused on neuronal cultures, either hippocampal neurons (Mabuchi 
et al., 2001) or in a neuronal-glial co-culture (Grabb & Choi, 1999). In this study, our main 
objective was to determine whether glutamate preconditioning would protect neurons from 
ischemia in an in vivo model.  To test this, we used transgenic (Tg) mice that overexpress 
glutamate dehydrogenase 1 (Glud1) in the neurons of the nervous system. These Tg mice are 
characterized by a lifelong increase in Glud1 activity and  increased synaptic glutamate release 
(Bao et al., 2009). We hypothesized that chronic exposure of brain neurons to moderate levels of 
glutamate would activate protective pathways that reduce damage after a stroke.  Our results 
demonstrate that the Glud1 Tg mice showed a decrease in infarct size and edema volume 
following middle cerebral artery occlusion (MCAO) when compared with wild type (Wt) mice. 
Furthermore, we explored the effect of preconditioning/ischemia on ubiquitin and Microtubule-
associated proteins-2 (MAP2).  
4.2 MATERIALS AND METHODS 
4.2.1 Generation of Glud1 Tg mice 
All experiments were conducted with the approval of the University of Kansas 
Institutional Animal Care and Use Committee.  The transgenic Glud1 mice were generated as 
described in Bao et al. (2009). Briefly, linearized DNA containing the cDNA of mouse Glud1 
was injected into fertilized C57BL6/SJL hybrid mouse oocytes. The cDNA was placed under the 
control of the Nse (neuron-specific enolase) promoter (Bao et al., 2009).The animals used for the 
following experiments were 9- mos of age as that was when differences between the Tg and Wt 
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become more significant.  Twenty two-month (mo) old mice were used for the studies on the 
effects of aging on ischemia- induced brain damage.  
4.2.2 In vivo ischemia model 
Reversible occlusion of the middle cerebral artery  was induced using a well-established 
protocol (Clark et al., 1997). The mice were anesthetized  with 3% Isoflurane and oxygen and 
maintained with 1.5% Isoflurane, or to desired anesthetic effect, throughout the procedure. 
Buprenorphine was used as the analgesic and was injected pre-operatively at 0.05 mg/kg.  Male 
mice were subjected to MCAO followed by a 24 hour (hr) period of reperfusion.  TTC (2,3,5-
triphenyltetrazolium chloride monohydrate) staining was used to assess brain damage (Ito et al., 
1997). Brain edema volume (Vedema) was also measured from the coronal sections that were 
stained by TTC by determining the volumes of both the ipsilateral (affected) hemisphere (VIpsi) 
and the contralateral hemisphere (Vcontra) and using the equation: Vedema =Vcontra - VIpsi (Yan et 
al., 2011). 
4.2.3 Measurement of proteasomal activity 
Brain tissues from 9-mo old Wt and Tg mice were homogenized and 20 μg of the cell 
homogenate were incubated with proteasome activity assay buffer in which their ability to cleave 
the flurogenic peptide substrate, Suc-LLVY-AMC was determined (Figueiredo‐Pereira et al., 
1994). The first assay buffer for evaluation of the 26S proteasome function consisted of 50 mM 
Tris (pH 7.4), 5mM MgCl2, 2 mM DTT, 2 mM ATP and the fluorogenic substrate Suc-LLVY-
AMC (80 μM in 1% DMSO, Sigma-Aldrich). The second buffer for determining 20S 
proteasome function contained 20 mM HEPES (pH 7.8), 0.5 mM EDTA, 0.03% SDS and 80 μM 
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Suc-LLVY-AMC. The hydrolysis of Suc-LLVY-AMC into AMC (7-amino-4-methly-coumarin) 
was detected with a fluorescence plate reader at ex 380 nm and em 440 nm.  
4.2.4 Immunohistochemistry 
Immunostaining and statistical analysis were conducted by Dr. Ranu Pal and performed 
using the protocol described by Bao et al., (2009). In brief, following fixation and 
permeabilization of hemisected brain tissue (ipsilateral vs. contralateral hemispheres); 2 mm 
coronal sections were obtained and further sectioned into ~25 m thick sections using a 
cryotome.  The thin sections were incubated overnight in the following primary antibodies: anti-
ubiquitin (polyclonal; rabbit; 1:250; Cell Signalling) and anti-MAP2A (monoclonal; mouse; 
1:250; Millipore). The sections were then rinsed in PBS and incubated with fluorescent dye-
labeled secondary antibodies (Alexa 488 goat anti-mouse and Alexa 568 rabbit anti-goat) at 37 
°C for 2 hrs. Images were acquired on a Leica SPE2 laser confocal microscope. Pixel density 
counts were determined using the Leica Application Suite software. The graphs represent 
averages from the stratum oriens (SO), stratum pyramidale (SP) and stratum radiatum (SR) of 
the CA1 and CA3 regions of the hippocampus from 3 pairs of animals.  
4.2.5 Statistical analysis  
Student’s t-test and three-way ANOVA analysis were used to determine statistical 
significance on SigmaPlot 12.5. 
4.3 RESULTS 
4.3.1 Decreased brain infarct and edema volume in the Glud1 Tg mice in the in vivo MCAO 
model of ischemic stroke 
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The 9-mo old Wt and Tg mice were subjected to MCAO followed by a 24 hr period of 
reperfusion. Using TTC staining, we were able to assess the extent of brain damage. The 
reduction of TTC by enzymes in living cells leads to the formation of water-insoluble formazan 
(red) and thus the area and volume of surviving tissue can be used to determine percent infarct 
size  (Ito et al., 1997). The results revealed that the Glud1 Tg mice had a 30% decrease in infarct 
volume compared to their Wt counterparts (Figure 4.1B). Brain edema volume was also 
measured using the 5 mm coronal sections by determining the difference between the volumes of 
both the ipsilateral hemisphere and the contralateral hemisphere. As shown in Figure 4.1C, the 
Glud1 Tg mice had a significantly lower edema volume following MCAO compared to the Wt 
mice. Together, these results support our hypothesis that chronic exposure to moderate levels of 
glutamate can protect against an ischemic insult.  
4.3.2 Increased basal levels of proteasomal activity 
Next, we aimed to elucidate the adaptive mechanisms that allowed the Glud1 Tg mice to 
be more resistant to ischemia. The ubiquitin-proteasome system (UPS) plays an essential role in 
ischemic tolerance (Meller et al., 2008; Meller, 2009). To identify the role of the UPS in this 
observation, we first determined proteasome activities in the preconditioned Glud1 Tg mice and 
the Wt mice. Brain tissues from 9-mo old Wt and Tg mice were homogenized and proteasomal 
function was assessed. An ATP-free assay buffer was used to differentiate 20S proteasomal 
function from the 26S proteasomal function. We found that basal activities of the 26S and the 
20S proteasome (without any prior treatment) were elevated in the Glud1 Tg mice (Figure 4.2). 
Although the significant increase in 26S proteasomal activity might suggest that this is due to 
increased protein ubiquitination as a result of the elevated glutamate levels, a previous study 
characterizing the Tg mice has concluded that accumulation of ubiquitin- 
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Figure 4.1 Effect of MCAO on brain tissue damage in Wt vs. Glud1 Tg mice. Brain damage 
was determined by TCC staining after mice were subjected to 90 min ischemia followed by 24 hr 
reperfusion. (A) Representative TTC staining of brain coronal sections proceeding from frontal 
to caudal. Sections were taken from the 1 mm position of the frontal pole and proceeded in 2 mm 
intervals to 5 mm. (B) Quantification of infarct volume was determined in TTC stained sections. 
(C) Quantification of brain edema volume estimated from TTC stained sections (n=5). Data 
presented as means ± SEM *P < 0.05, vs. Wt mice.  
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Figure 4.2. Brain proteasomal activity is increased in the Glud1 Tg mice. Activities of the 
(A) 26S and the (B) 20S proteasome were assayed by determining their ability to cleave Suc-
LLVY-AMC (n=3). Data presented as means ±SEM *p<0.05, vs. Wt mice. 
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protein aggregates do not appear until the age of 16-20 mo (Bao et al., 2009). This was 
confirmed in recent studies using 9 mo-old Tg and Wt mice as will be presented below. This 
suggests that at 9 mo, proteasome overload has not yet occurred. 
4.3.3 Ubiquitin labeling in hippocampus following MCAO 
To determine whether the increase in proteasome activity had an effect on ubiquitin and 
ubiquitinated proteins, we stained brain sections from Glud1 Tg and Wt mice after cerebral 
occlusion. Changes in the levels of ubiquitin and whether there is an even distribution of 
ubiquitin immunoreactivity or ubiquitin-positive aggregates present is a strong indicator of 
protection induced by glutamate preconditioning. In a review by Caldeira et al, it was noted that 
the formation of ubiquitin-protein aggregates  is a protective response of cells against abnormal 
proteins and suggest a greater potential for cell survival in the immediate post-ischemic period 
(Caldeira et al., 2014). As shown in figure 4.3A, ubiquitin levels seemed to increase in the CA1 
region of the hippocampus in the Glud1 Tg mice with an even higher increase in the CA3. This 
change however was not statistically significant presumably due to the high variation in the mean 
pixel density (Figure 4.3B). Additional experiments to increase the sample size may provide 
more conclusive results. The ubiquitin labeling seemed to be evenly distributed in the areas with 
the high levels of ubiquitin with few ubi-protein aggregates. Damaged proteins can form toxic 
aggregates (Taylor et al., 2002) and indicate a reduction in cell viability or the presence of 
vulnerable cells that are destined to die (Ge et al., 2007). To confirm that the changes in 
ubiquitin levels were due to the effect of ischemia, levels of ubiquitin from the hippocampus of 
Glud1 Tg and Wt that were not subjected to MCAO were also determined (Figure 4.3C).  The 
results showed no significant differences between the CA1 and CA3 of the Glud1 Tg and Wt 
mice (Figure 4.3D).  
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Figure 4.3A Ubiquitin expression in Glud1 Tg and Wt mice after MCAO. Representative 
immunofluorescent images showing labeling of ubiquitin in the ipsilateral CA1 and CA3 region 
of the hippocampus of a pair of 9-mo old Glud1 Tg and Wt mice that were subjected to in vivo 
ischemia/reperfusion and processed for immunohistochemical studies at the same time. SO,  
stratum oriens; SP, stratum pyramidale; SR stratum radiatum.  
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Figure 4.3B Quantification of ubiquitin expression in Glud1 Tg and Wt mice after MCAO. 
The mean pixel density of ubiquitin expression was determined from the multiple subfields of 
the ipsilateral CA1 and CA3region from 3 pairs (Glud1 Tg and Wt) of mice. All data are 
presented as means ±SEM (n=3).  
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Figure 4.3C Baseline ubiquitin expression in Glud1 Tg and Wt mice. Representative 
immunofluorescent images showing labeling of ubiquitin in the CA1 and CA3 region of the 
hippocampus of a pair of 9-mo old Glud1 Tg and Wt mice that were processed for 
immunohistochemical studies at the same time. SO,  stratum oriens; SP, stratum pyramidale; SR 
stratum radiatum.  
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Figure 4.3D Quantification of  baseline ubiquitin levels in Glud1 Tg and Wt mice. The mean 
pixel density of ubiquitin expression was determined from the multip le subfields of the CA1 and 
CA3region from 3 pairs (Glud1 Tg and Wt) of mice. All data are presented as means ±SEM 
(n=3). SO,  stratum oriens; SP, stratum pyramidale; SR stratum radiatum. 
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4.3.4 MAP2 labeling is increased in the Glud1 Tg mouse hippocampus following MCAO 
MAP2 is critical for the maintenance of normal cytoskeletal architecture and functions 
(Yan et al., 2010). MAP2 is a useful marker of neuronal cell bodies and dendrites, not axons, and 
was previously used to demonstrate that the chronic elevations in glutamate release in the Tg 
mice were associated with a gradual deterioration of dendrites and cell death of particularly 
sensitive neurons, such as those in the CA1 region of the hippocampus (Bao et al., 2009). 
Therefore, MAP2A immunoreactivity was used as a neuronal marker in the present study, as 
well. Notable differences were observed between the Glud1 Tg mice and the Wt mice.  Unlike 
the baseline condition where MAP2A immune- labeling is significantly stronger in Wt than Tg 
mice (Figure 4.4), MAP2 levels were significantly increased (p<0.003) in the CA1 region of the 
hippocampus in the Glud1 Tg mice following ischemia. Although the CA3 region showed an 
increasing trend in MAP2 labeling, the differences were not statistically significant.  
4.3.5 Effect of aging on the MCAO response of Wt and Tg animals 
Focal ischemia has been shown to increase the infarct volume  in aged animals (Davis et 
al., 1995; Sutherland et al., 1996) and the effectiveness of preconditioning-induced protection 
against severe ischemia has been reported to decrease with age (He et al., 2005).To determine 
whether the tolerance induced by our model of in vivo glutamate preconditioning was preserved 
in aged mice, we used TTC staining to calculate the infarct and edema volume  in 22-mo old 
mice after MCAO and reperfusion. Figure 4.5 shows the Glud1 Tg mice at 22 mos were still 
protected in terms of a decrease in infarct and edema volume compared to their age-matched Wt 
counterparts. No significant differences were found between the 22-mo old and the 9-mo old 
mice of the same genotype. 
129 
 
 
 
Figure 4.4A Immunolabeling of MAP2 in Glud1 Tg and Wt mice after MCAO. 
Representative immunofluorescent images showing labeling of MAP2  in the ipsilateral CA1 and 
CA3 region of the hippocampus in a pair of 9-mo old Glud1 Tg and Wt mice that were subjected 
to in vivo ischemia/reperfusion and processed for immunohistochemical studies at the same time. 
SO,  stratum oriens; SP, stratum pyramidale; SR stratum radiatum.  
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Figure 4.4B Quantification of MAP2 immunolabeling in Glud1 Tg and Wt mice after 
MCAO. The mean pixel density of MAP2expression was determined from the multiple subfields 
of the ipsilateral CA1 and CA3 region from 3 pairs (Glud1 Tg and Wt) of mice. All data are 
presented as means ±SEM (n=3).   
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Figure 4.4C Baseline MAP2 expression in Glud1 Tg and Wt mice. Representative 
immunofluorescent images showing labeling of MAP2  in the ipsilateral CA1 and CA3 region of 
the hippocampus in a pair of 9-mo old Glud1 Tg and Wt mice that were processed for 
immunohistochemical studies at the same time. SO,  stratum oriens; SP, stratum pyramidale; SR 
stratum radiatum.  
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Figure 4.4D Quantification of baseline MAP2 levels in Glud1 Tg and Wt mice. The mean 
pixel density of MAP2expression was determined from the multip le subfields of the CA1 and 
CA3 region from 3 pairs (Glud1 Tg and Wt) of mice. All data are presented as means ±SEM 
(n=3). SO,  stratum oriens; SP, stratum pyramidale; SR stratum radiatum.  
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Figure 4.5. Effect of MCAO on brain tissue damage in 22 month old Wt and Glud1 Tg 
mice. Brain damage was determined by TCC staining in 9-mo and 22-mo old Wt and Glud1 Tg 
mice after 90 min ischemia followed by 24 hr reperfusion. (A) Representative TTC staining of 
brain coronal sections proceeding from frontal to caudal. Sections were taken from the 1 mM 
position of the frontal pole and proceeded in 2 mm intervals to 5 mm. (B) Quantification of 
infarct volume determined by TTC stained sections. (C) Quantification of brain edema volume 
estimated from TTC stained sections (n=3). Data presented as means ± SEM *P < 0.05, vs. Wt 
mice.  
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4.4 DISCUSSION 
Stroke is a debilitating disorder with no effective neuroprotective therapy. Treatments for 
ischemic stroke are required to limit stroke induced morbidity and mortality as recombinant 
tissue plasminogen activator (rt-PA) is the only pharmacological agent that has been approved to 
treat acute ischemic stroke. Rt-PA is administered to only 2-5% of stroke patients due to the 
strict eligibility criteria (Donnan et al., 2011). Since rt-PA is a thromolytic, it is considered an 
indirect neuroprotectant (Minnerup et al., 2012) and strategies that directly target neuronal 
viability are still unavailable. A study that investigated the biochemical alterations in the peri-
infarct tissue of stroke patients showed that extracellular glutamate was elevated  after ischemia 
and remained elevated in patients that showed infarct progression over time (Woitzik et al., 
2014). This suggests that excitotoxicity is not only associated with the initial cell death following 
a stroke but also with delayed infarct progression.   
In the current study, we showed as a proof-of-concept that the protective effect of 
ischemic tolerance can also be observed by substituting a short period of ischemia 
(preconditioning) with chronic, moderate hyperactivity of glutamate in brain. Glud1 Tg mice 
were used as our in vivo model of glutamate preconditioning.  Glud1 is a mitochondrial enzyme 
that is involved in the glutamate biosynthesis pathway. It catalyzes the catabolism of glutamate 
to α-ketoglutarate (α-KG). Glud1 also catalyzes the reverse reaction to convert α-KG and 
ammonia back to glutamate (Stewart et al., 1980). The Tg mice that were created over-express 
the Glud1 gene, have increased enzymatic activity and were shown to have moderate increases in 
Glu levels compared to their Wt littermates (Bao et al., 2009). Unlike a previous mouse model 
that was a null mutant for the glutamate EAAT2 transporter (Rothstein et al., 1996; Tanaka et 
al., 1997) these Tg mice do not suffer from brain damage (until an older age) and have a 
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relatively longer life span (Bao et al., 2009). We subjected 9-mo Glud1 Tg mice to MCAO to 
induce in vivo ischemia followed by a 24 hr period of reperfusion. Interestingly, the Glud1 Tg 
mice were more resistant to brain damage compared to the Wt, “non-preconditioned” mice. We 
then sought to determine possible mechanisms that are involved in the adaptive response to 
chronic glutamate exposure.  
The proteasomal proteolytic pathways represent the main mechanisms responsible for the 
degradation of damaged or unwanted proteins. These pathways play a very significant role in 
maintaining normal, cellular homeostasis. Knockouts of proteasomal subunits have resulted in 
lethal phenotypes (Heinemeyer et al., 1991; Orlowski, 1999), further indicating their importance. 
Protein unfolding and aggregation are dominant pathogenic events in the vulnerable ischemic 
neurons(Ge et al., 2007). The irreversible accumulations of protein aggregates are often toxic to 
cells and can cause neuronal death.  Protein ubiquitination involves a sequential process in which 
ubiquitin forms a thioester bond with an E1-ligase (requires ATP), then it is transferred to the 
E2-ligase and finally it is transferred from the E2-ligase to the target protein by an E3-ligase 
(Hershko, 1983). Ubiquitin is usually ligated to the exposed hydrophobic segments of unfolded 
proteins that need to be degraded. If ubi-proteins become too numerous to be degraded by the 
proteasome, they tend to aggregate. A study by Lui et al. (2005) showed that ischemic 
preconditioning was able to alleviate protein aggregation in neurons. Whether this reduction is 
due to a decrease in overall cell damage or because tolerant cells have an enhanced ability to 
eliminate the irreparably damaged proteins has yet to be elucidated. It is known that excess 
glutamate can induce the formation of ROS (Armstead et al., 1989; Duchen, 2000; Kahlert et al., 
2005; Parfenova et al., 2006) and that ROS can alter proteasomal activities as shown by us 
(Chapter 2) and previous reports (Ullrich et al., 1999; Ding et al., 2003; Grune et al., 2004; 
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Aiken et al., 2011). Therefore, we hypothesized that glutamate can indirectly lead to an increase 
in proteasomal activity that could be protective following ischemia and reperfusion. Initially we 
determined that glutamate preconditioning increased basal proteasomal activities in the Glud1 Tg 
mice. We then looked at the levels of ubiquitin to determine whether the proteasomal activity 
was preserved or compromised after the ischemic insult.   
The increasing trend in the ubiquitin- immunoreactive proteins (Figure 4.3) suggests that 
an enhancement in 26S proteasomal activity may not play a role in this protective effect. A 
previous report characterizing the Glud1 Tg mice showed that although the 9-mo old Glud1 mice 
had only marginally higher ubiquitin levels compared to their Wt counterparts, examination of 
16-20 mo old mice showed intense levels of ubiquitin staining in the Glud1mice compared to the 
almost non-existent staining in the Wt mice (Bao et al., 2009). We confirmed this observation as 
shown in Figure 4.3C.  It is reasonable to believe that the ischemic stress that occurred in our 
study at 9-mo was able to trigger whatever changes in the ubiquitin-proteasome system that 
would cause these observations at 16-20 mos (an additional 7-11 mos of glutamate exposure).  
Furthermore, analysis of the genome-wide gene expression in the hippocampus of the Glud1 
mice showed that there were not only an upregulation in Ubiquitin-Specific Peptidases that 
degrade ubiquitinated proteins, but also increases in Ubiquitin-Conjugating Enzymes such as 
UBE2K and UBE3A, which covalently attach ubiquitin molecules to proteins that are destined 
for degradation  (Wang et al., 2010a).  Whether a longer reperfusion period (>24 hrs) would 
ultimately result in an increase in delayed neuronal death in the Glud1 Tg mice is still unknown.  
The increase in basal proteasomal activity (Figure 4.2) could be a compensatory 
mechanism to deal with the effects of the moderate increases in glutamate. Following a stroke, 
the loss of ATP can impair the activities of the 26S proteasome (Keller et al., 2000). The 26S 
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proteasome, is an ATP-dependent protease composed of a core proteinase, the 20S proteasome, 
that is capped with two PA700 regulatory particles (the 19S complex)  on both ends (Coux et al., 
1996). Tanahashi et al. demonstrated that in vitro, these subunits associate and disassociate in an 
ATP-dependent manner. ATP-rich conditions promote their association and the formation of the 
enzymatically active 26S proteasome and conditions lacking ATP causes their disassociation 
(Tanahashi et al., 2000).  Following transient forebrain ischemia, the ATP-dependent re-
association of the 20S catalytic and PA700 regulatory subunits to form the 26S proteasome was 
severely impaired in the hippocampus (Asai et al., 2002).  
It is important to note that although the differences in ubiquitin immunostaining between 
the CA1 and CA3 regions of the hippocampus in the Glud1 Tg mice were not statistically 
significant it seems as though ubiquitin was present in higher levels in the CA3 (Figure 4.3). This 
is interesting because the CA1 is usually more sensitive than the CA3 when exposed to oxidative 
stress as shown by previous reports (Sarnowska, 2001; Wang et al., 2005).  More specifically, 
Bao et al. showed that the CA3 was more resistant to neuronal loss than the CA1 in the Glud1 Tg 
mice. The more vulnerable CA1 region also had decreased MAP2A labeling of dendrites and in 
synaptophysin labeling of presynaptic terminals  (Bao et al., 2009).  The CA1 has higher 
superoxide levels and  increases in both anti-oxidant genes and genes related to the formation of 
ROS (Wang et al., 2005). Aiken et al. (2011) proposed a mechanism by which the proteasome 
can cope with oxidative stress through compositional and structural changes that modulate their 
activity.  Oxidative stress triggers the disassembly of the 26S thus liberating the 19S particle and 
the 20S complex and increasing the ATP and ubiquitination- independent removal of oxidized 
proteins (Aiken et al., 2011). At this point this disassembly is reversible  (Wang et al., 2010b), 
however with prolonged exposure de novo proteasome synthesis is activated (Ding et al., 2003). 
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This upregulates both standard and inducible (immunoproteasomes) proteasomal components 
that are more functional  (Pickering et al., 2010)  with amplified specific endopeptidase activities 
(Driscoll et al., 1993) that are better able to degrade oxidized proteins than the standard 26S 
proteasome   (Aiken et al., 2011).  Protection induced by ischemic preconditioning was lost in 
mice with immunoproteasome subunit deficiencies (Cai et al., 2008). 
Microtubule-associated proteins (MAPs) are key regulators of neural morphogenesis 
(Popa-Wagner et al., 1999). During morphogenesis, early stage MAPs (MAP1B, juvenile tau, 
and MAP2c) are replaced with “late” MAPs which include MAP2B and MAP2B. These late 
MAPs have a profound effect on the organization of cellular microtubules (Lewis et al., 1989) 
and provide structural stabilization and process outgrowth (Chen et al., 1992), so that proper 
synaptic circuitry is maintained in the mature brain (Marsden et al., 1996; Popa-Wagner et al., 
1999).  MAP2A is preferentially associated with dendritic processes (Binder et al., 1986) 
implicating a role in neuronal morphogenesis. Previous studies have reported that stress 
conditions can alter MAP2 levels in the brain cortex and hippocampus (Yan et al., 2010).  MAP2 
localization and protein levels were disrupted in response to excitotoxicity  (Arias et al., 1997).  
Cerebral ischemia reduced MAP2 immunoreactivity in the hippocampus and cortex of neonatal 
rats (Malinak & Silverstein, 1996) and adult  rats (Kitagawa et al., 1989; Dawson & Hallenbeck, 
1996). The most significant loss of MAP2 following ischemia was in the CA1 region in both rats 
(Inuzuka et al., 1990) and gerbils (Yoshimi et al., 1991).  The susceptibility of MAP2 to 
ischemia and excitotoxicity was attributed to the elevation of intracellular Ca2+ concentrations 
cause rapid MAP2 proteolysis by calcium-activated proteinases (Kitagawa et al., 1989). In 
Figure 4.4 we demonstrate that following MCAO, MAP2 was significantly increased in the CA1 
region of the Glud1 Tg mice compared to their Wt littermates. This increase in immunolabeling 
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is more likely a result of increased protein levels and not an increase in the number of dendritic 
processes.  This suggests that unlike the Wt mice, the Glud1 Tg may have a preserved ability to 
synthesize some of the components required for structural repair and maintenance (Popa-Wagner 
et al., 1999). Since MAP2 is synthesized in the cell body and then transported to dendrites 
(Okabe & Hirokawa, 1989).  This suggests that the Glud1 Tg mice could also have improved 
protein transport that enhances recovery after cerebral ischemia.  
Previous studies have reported that the degree of preconditioning- induced protection is 
significantly diminished in aged rats (Fenton et al., 2000; He et al., 2005).  In humans, transient 
ischemic attacks (TIA) were found to be neuroprotective against ischemic strokes. However, the 
protective mechanisms of TIAs were not present in elderly patients over the age of 65 as there 
were no significant differences in stroke severity between patients with and without TIAs (Della 
Morte et al., 2008). To determine whether the tolerance induced by glutamate preconditioning 
was preserved in aged mice, we evaluated brain infarct size in 22-mo old Glud1 Tg mice after 
MCAO and reperfusion. We show that glutamate preconditioning was at least, if not more, 
effective in the aged (22-mo) versus the young adult (9-mo) mice. This was consistent with a 
study done by Dowden et al. (1999) in which they preconditioned gerbils with 1.5 min of 
ischemia before a subsequent 5-min occlusion of both carotid arteries (global ischemia). In 
young animals they reported 53-66.5% protection of CA1 neurons and approximately 75% 
protection in aged preconditioned gerbils (Dowden & Corbett, 1999). The authors attributed this 
difference to the decrease in density and sensitivity of N-methly-D-aspartate (NMDA) receptors 
that occur in the aged rodent brain (Gonzales et al., 1991).  
 In conclusion, the phenomenon of ischemic preconditioning in the brain is well 
documented. However, for the first time we show that an in vivo model of glutamate 
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preconditioning was also able to induce tolerance and maintain cell viability in young adult mice 
that were subjected to cerebral occlusion. This protection was preserved in the aged 22-mo old 
mice. The results from the ubiquitin immunostaining remain inconclusive and additional studies 
will be required to further elucidate the role of the ubiquitin-proteasome system in the adaptive 
mechanisms that contribute to the induced tolerance. Even with the increasing trend of ubiquitin 
(lack of statistical significance) in the Glud1 Tg, the brain infarct was decreased .The increase in 
MAP2 levels may suggest an enhancement in protein synthesis and transport in the Glud1 Tg 
mice. In that case, the increase in ubiquitin may also be a result of increased overall protein 
synthesis. Ubiquitin is an indispensable protein that is required to maintain cellular repair and its 
depletion can have deleterious effects on cell viability (Hanna et al., 2003).  Yamashita et al. 
(1991) showed that mild hypothermia prevented delayed CA1 neuronal damage. They reported 
that increased ubiquitin synthesis and protein ubiquitination was an essential part of the 
protective mechanism (Yamashita et al., 1991).  Liu et al. show that ischemic preconditioning 
increased levels of free ubiquitin  (Liu et al., 2005). Future studies can be carried out to 
determine other molecular markers for growth, repair processes and protein synthesis.  
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5.1 FUTURE DIRECTIONS  
5.1.1 Determining the mechanisms of HIF-1α stabilization in astrocytes  
Although the endpoint for stroke therapy is to preserve neuronal function, it is important 
to study astrocytes and determine what adaptive mechanisms can improve their function and 
viability following ischemia. The importance of targeting astrocytes to ensure neuronal survival 
is described in detail in chapter 3. Therefore, future studies can be carried out to understand the 
potential mechanisms of HIF-1α degradation during ischemia in astrocytes. Preliminary studies 
showed that the activity of both the 26S and 20S proteasome was affected by in vitro ischemia 
(Figure 5-1). Proteasomal inhibition by MG-132 increased cell viability (Figure 5.2A) and this 
was correlated with increased HIF-1α protein stabilization (Figure 5.2B).  
5.1.2 Antioxidant therapy in ischemic stroke  
It has been well established that oxidative stress causes tissue damage following a stroke. 
During ischemia and reperfusion, there is a surge in the production of free radicals that lasts for 
at least 6 to 12 hrs (Flamm et al., 1978; Amaro & Chamorro, 2011). This led to numerous studies 
that targeted the use of antioxidants to preserve neuronal function. Antioxidants such as Ebselen, 
Tirilazad, and NXY-059 were even tested in phase III clinical trials (Shi, 2009), however, they 
did not demonstrate beneficial effects in the trials despite the promising preclinical results. Those 
studies aimed at taking advantage of the antioxidant’s ROS scavenging properties and their 
ability to reduce lipid peroxidation. In chapters 2 and 3 however, we show how ROS plays a 
critical role in regulating HIF-1α stabilization and degradation during ischemia. Using 
antioxidants to target this novel pathway can prove to be effective in providing neuronal and 
astrocytic protection. 
150 
 
 
Figure 5.1 Oxygen/glucose deprivation (OGD) increases proteasomal activity in astrocytes. 
Primary cortical astrocytes were exposed to either normoxia (N) or OGD for 90 min and then the 
26S and 20S proteasomal activity was determined (as described in section 2.3.2 Materials and 
Methods) from the lysates. The increase in both the 26S and 20S proteasome activity following 
OGD exposure was found to be significant. *p < 0.05 vs. normoxia. (n=3) 
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Figure 5.2 Proteasome inhibition by MG-132 increases astrocyte viability and stabilizes HIF-1α 
protein levels. (A) Astrocytes were pre-treated with a range of MG-132 concentrations (0, 10, 40 
and 80 μM) and then exposed to OGD. Cell viability was assessed using the MTT assay. *p <0.05 
versus normoxia (N), #p <0.05 versus OGD. (n = 3). (B) Representative immunofluorescent 
images showing MAP-2 (red) and HIF-1α (green) labeling in astrocytes exposed to normoxia or 
OGD for 90 min.  Astrocytes were also pre-treated with 40 μM MG-132 and then subjected to 
OGD. (n=3) 
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Future studies will be done to determine the specific free radical species that contribute to 
HIF-1α degradation and which antioxidants can prevent the ROS-mediated increase in 
proteasomal activity. In our study we used proteasomal inhibitors to directly stabilize HIF-1α. 
However, we did not do any long-term studies (greater than 24 hrs) to determine any side-effects 
or neurotoxicity that can arise from inhibiting the proteasome. It is possible that an indirect 
approach of reducing the ROS responsible for the proteasome-mediated HIF-1α degradation 
versus the use of proteasome inhibitors could be more effective long-term. Therefore, future 
studies can also include a comparison between specific antioxidant therapy and proteasomal 
inhibition on preserving cell viability in both in vitro and in vivo models.   
5.1.3 The effect of glutamate exposure on mitochondrial function in stroke  
Mitochondria play a pivotal role in the regulation of neuronal survival and death. Their 
main function is energy production through respiration; however they are also involved in 
cellular apoptosis (Schon & Przedborski, 2011). During ischemia, the accumulation of Ca2+ 
through the over-activation of glutamate receptors (Liu et al., 2009b) subsequently promotes 
mitochondrial dysfunction which is characterized by an increase in mitochondrial permeability, 
altered mitochondrial membrane potential (∆Ѱm) , activation of caspases through cytochrome C 
release and an increase in ROS formation (Brookes et al., 2004; Liu et al., 2009b). The uptake of 
Ca2+ into mitochondria is driven by the ∆Ѱm (Brookes et al., 2004) which is maintained by the 
mitochondrial enzymes of electron transport chain (ETS). Alterations in the enzymatic 
complexes of the ETS can have detrimental effects and has been shown to occur during brain 
ischemia. Complex I and complex III are the main contributors to the formation of ROS and 
increased oxidative stress (Liu et al., 2002). Mitochondria are a major source of ROS; however 
they are also a target of ROS. For example, lipid peroxidation has been shown to modify 
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mitochondrial proteins and alter their function (Lucas & Szweda, 1998). Therefore, future work 
should study the effect of glutamate exposure on mitochondrial function and homeostasis and 
how that can affect the outcome of a stroke. Studies should focus both on the effect of glutamate 
toxicity (chapter 3) and glutamate as a preconditioning stimulus (chapter 4).  Given that HIF-1α 
protected astrocytes during glutamate toxicity and that it has been shown to be a regulator of 
mitochondrial metabolism during ischemic preconditioning (Semenza, 2011), the role of HIF-1α 
under these conditions should also be determined. 
During ischemia or ischemic preconditioning, cells will compensate by altering their 
metabolic pathways to adapt to the new anaerobic environment. In preliminary studies, we 
looked at these alterations by using the Seahorse XF96 Extracellular Flux analyzer (Figure 
5.3). This method provides a real-time reading of pH which is indicative of changes in lactic 
acid levels and ultimately of glycolytic activity.  It also measures oxygen consumption which 
relates the levels of oxidative phosphorylation, providing an effective assessment of 
mitochondrial function. We used a sublethal preconditioning stimulus of glutamate to induce 
an ischemic-tolerant state and determined the effect on astrocyte mitochondrial function after 
OGD exposure. Our results indicated that the moderate glutamate exposure provided 
mitochondrial protection against ischemic insults in astrocytes by increasing an adaptive 
mechanism that involves improved maximum mitochondrial respiration capacity (MRC) and 
spare respiratory capacity (SRC) (Brand & Nicholls, 2011). In addition, inhibiting HIF-1α with 
YC-1 or 2Me2 prevented the mitochondrial protection conferred by the glutamate 
preconditioning. Further studies should be conducted to confirm this in neurons and in the in 
vivo model of chronic glutamate exposure (Glud1 Tg mice).  Other mitochondrial function 
parameters such as the mitochondrial membrane potential and activities of complexes I-IV of  
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Figure 5.3 Assessment of mitochondrial function using the Seahorse XF96 Extracellular Flux 
analyzer. Measurement of oxygen consumption rate (OCR) in primary cortical astrocytes 
preconditioned with 0, 0.25, 0.1, 1 and 5 μM of glutamate (Glu) for 72 hrs then exposed to 90 min of 
oxygen and glucose deprivation (OGD). The XF96 Extracellular Flux analyzer sequentially exposed the 
cells to oligomycin (ATP synthase inhibitor), FCCP (mitochondrial uncoupler) and then a mix of 
rotenone and antimycin (inhibitors of Complex I and III respectively) (n = 3). 
155 
 
  
 
   
   A 
   B 
156 
 
Figure 5.4 HIF-1 inhibition with YC-1 and 2-Me2 prevents the protective effect of 
preconditioning. Measurement of (A) maximum respiratory capacity (MRC) and (B) spare 
respiratory capacity (SRC) in primary cortical astrocytes preconditioned with 0, 0.25, 0.1, 1 and 
5 μM of glutamate (Glu) for 72 hrs and then subjected to 90 min of oxygen and glucose 
deprivation (OGD). Astrocytes were pre-treated with the HIF-1 inhibitors, YC-1 and 2-Me2 
(0.1mM) for 1 hr prior to OGD exposure. *p < 0.05 vs. control OGD + 0 μM Glu, #p <0.05 YC-
1 treated cells vs. OGD of same Glu concentration with no HIF-1 inhibitor, ^p <0.05 2Me2 
treated cells vs. OGD of same Glu concentration with no HIF-1 inhibitor (n = 3). 
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of the electron transport system should also be evaluated. The mitochondrial potassium ATP 
channel (mK+ATP) on the inner membrane of the mitochondria has been suggested to play a more 
pronounced role in ischemic tolerance than the channels that reside on the plasma membrane 
(Schultz et al., 1997; Obrenovitch, 2008; Liu et al., 2009a). Activation and opening of the 
mK+ATP protected cortical cells from hypoxia (Domoki et al., 1999; Liu et al., 2003). mK
+
ATP 
antagonists abolished the effects of preconditioning (Hide & Thiemermann, 1996) and mK+ATP  
agonists leads to ischemic tolerance (Oldenburg et al., 2002; Shimizu et al., 2002; Kis et al., 
2004). Furthermore, opening the mK+ATP with diazoxide protected retinal cell cultures from 
glutamate exposure (Roth et al., 2006). It has been suggested that this protection could be due to 
mK+ATP depolarizing the mitochondrial membrane potential and causing an increase in electron 
transport chain activity and thus more ATP production (Schultz et al., 1997). We evaluated the 
levels of the mK+ATP channel in our in vivo model of glutamate preconditioning. The results 
showed that mK+ATP channel immunolabeling was increased in the CA1 and CA3 hippocampus 
of the Glud1 Tg mice compared to the Wt mice (Figure 5.5). Understanding the effect of mK+ATP 
channel upregulation on mitochondrial preservation would be a promising avenue to pursue in 
the future.  
5.1.4 Glutamate preconditioning and antioxidant capacity 
The level of antioxidant capacity in astrocytes and neurons would predict the level of 
brain ischemic tolerance induced by preconditioning.  Therefore, an assessment of whether long-
term mild glutamate exposure increases cellular antioxidant capacity in in vitro and in vivo 
models of ischemia should be considered. Activities of superoxide dismutase, glutathione 
peroxidase, and xanthine oxidase can be evaluated using colorimetric assay kits and levels of  
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Figure 5.5A mK+ATP expression in Glud1 Tg and Wt mice after MCAO. Representative 
immunofluorescent images showing labeling (as described in section 4.2.4 Materials and 
Methods) of mK+ATP in the ipsilateral CA1 and CA3 region of the hippocampus in 9-mo old 
Glud1 Tg and Wt mice that were subjected to in vivo ischemia/reperfusion. SO,  stratum oriens; 
SP, stratum pyramidale; SR stratum radiatum.  
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Figure 5.5B Quantification of mK+ATP immunolabeling in Glud1 Tg and Wt mice after 
MCAO. The mean pixel density of mK+ATP expression was determined from the multiple 
subfields of the ipsilateral CA1 and CA3 region from 3 pairs (Glud1 Tg and Wt) of mice. All 
data are presented as means ±SEM (n=3).   
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different ROS species can be measured. Any relationships with HIF-1α stabilization or 
regulation can also be determined. 
5.2 CONCLUSIONS 
In summary, this dissertation aimed to investigate endogenous pathways by which the 
brain might protect itself from ischemia. The current therapy that is available following a stroke 
remains suboptimal and the need for the development of treatment options still exists. 
Understanding the mechanisms by which cells adapt in response to an ischemic insult is a very 
plausible approach to minimizing brain damage and improving stroke outcome. Even without 
preconditioning, brain cells naturally respond to hypoxia by triggering a host of defenses to 
counter cell injury and death (Sapolsky, 2001); the most critical of these responses being the 
stabilization of HIF-1α. Thus HIF-1 is part of the fundamental endogenous protective responses 
that occur after stroke that are innate but also adaptive following a preconditioning stimulus. In 
the first part of this work, we explored a different mechanism by which HIF-1α can be degraded 
during ischemia. We investigated the effects of ROS and ischemia on proteasomal activities in 
primary cortical neurons and showed that they resulted in increased 20S proteasomal activity. 
The 20S proteasome targets and degrades oxidized proteins and as we hypothesized, HIF-1α 
oxidation by ROS formed during ischemia made it susceptible to degradation by the 20S 
proteasome. The use of the proteasome inhibitors MG-132 (for in vitro experiments) and 
Epoxomicin (for in vivo experiments) increased HIF-1 accumulation and reduced ischemia-
induced cytotoxicity. 
The release of glutamate is the major cause of brain damage following a stroke; therefore, 
in the third chapter of this dissertation we determined HIF-1α expression and stabilization in 
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response to glutamate toxicity during hypoxia. We targeted astrocytes in this study given their 
role in glutamate uptake release and because they are critical determinants of both neuronal 
viability and functional recovery after stroke (Zhao & Rempe, 2010). We show that HIF-1α 
stabilization protects astrocytes from glutamate- induced damage while it’s inhibition by 2-Me2 
and YC-1 attenuated the recovery of astrocytes under hypoxia.  Furthermore, GSH promotes 
HIF-1α protein stabilization which is consistent with our previous results that demonstrate how 
ROS can cause HIF-1α degradation. Inhibition of GSH with BSO reduced HIF-1α expression 
and abolished the HIF-1 mediated protection of astrocytes.  
Finally, we investigated the effect that a life- long release of moderate levels of glutamate 
would have on the glutamate dehydrogenase 1 (Glud1) transgenic (Tg) that were subjected to 
middle cerebral artery occlusion (MCAO). Evaluation of the brain damage that occurred after 
MCAO revealed that the Glud1Tg mice had a reduced infarct and edema volume compared to 
their wild type counterparts. In addition, immunostaining of the CA1 and CA2 regions of the 
hippocampus showed that the Glud1 Tg mice had increased ubiquitin and MAP2 levels. While 
the ubiquitin results were inconclusive, the increase in MAP2 is indicative of an adaptive 
protective response that enhances protein synthesis and transport. Interestingly, although 
previous studies have reported that the ischemic tolerance phenomenon is not as effective in aged 
animals as it is in younger animals, our studies have shown that the significant decrease in infarct 
volume in the 9-month old Tg mice was also seen in the aged mice (22 months old). Therefore, it 
can be concluded that glutamate preconditioning is an effective approach for inducing ischemic 
tolerance.  
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